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Abstract 
Regulation of Anoikis by ankyrin complexes 
Sanjeev Kumar 
Anoikis is a subset of apoptosis, suppressed by cell-extracellular matrix 
association. It is a safeguard mechanism against tumor metastasis. The present study 
was designed to understand the role of cortical cytoskeletal protein ankyrin-G and its 
interacting proteins in anoikis. E-cadherin and ankyrin-G are function partners and during 
epithelial-mesenchymal-transition (EMT), both gets downregulated. During cell-
extracellular matrix dissociation, ankyrin-G shifts to cytoplasm from cytoskeleton and 
loses spectrin interaction. Overexpression of ankyrin-G induced apoptosis in death 
domain dependent manner, promoted by the presence of ankyrin-G death domain 
interacting partner, RIP1 (Receptor Interacting Protein with death domain). Ankyrin-G also 
interacted with a MAGE family protein NRAGE (Neurotrophin Receptor Interacting mAGE 
protein), which suppressed ankyrin-G induced apoptosis.  
NRAGE suppressed anoikis and promoted anchorage independent growth. It was 
also upregulated in the cells which have undergone EMT as well as in various other 
tumor types. The oncogenic transcription repressor TBX2 (T-Box Protein) interacted with 
NRAGE and co-operated functionally in anoikis suppression and anchorage independent 
growth. Ankyrin-G sequestered NRAGE in cytoplasm and counteracted NRAGE 
mediated transcription activity. NRAGE also affected E-cadherin mediated adherens 
junction kinetics and activated pro-survival signaling in cells dissociated from extracellular 
matrix. 
We report a novel pathway, controlled by E-cadherin and ankyrin-G, sequestering 
NRAGE in cytoplasm in epithelial cells. During EMT, loss of E-cadherin and ankyrin-G 
promotes NRAGE localization to nucleus. NRAGE co-operates with TBX2 in suppressing 
anoikis and promoting anchorage independent growth.   
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CHAPTER 1 
LITERATURE REVIEW 
Introduction 
An epithelial cell is characterized by its apical-basolateral polarity and the basic 
framework is supported by basement membrane or extracellular matrix (ECM) and cell-
cell junctions. The cell-cell and cell-membrane interactions involve various junction 
proteins which are known to control their assembly into tissues and organs through a 
process called cell adhesion. The adhesion properties of cells are supported and 
regulated by the cytoskeleton which links the cytoplasm to specialized junctions in plasma 
membrane. The epithelial cell homeostasis is tightly regulated by features such as cell-
cell contact inhibition and requirement for growth signal. The epithelial cells such as in the 
gastro-intestinal tract, mammary and prostate glands have very high turnover rate and 
any defects either constitutively or during tissue remodeling affecting cell homeostasis, 
results into uncontrolled cell proliferation and development into cell carcinoma. Cell 
carcinomas (cancer arising from epithelial cells) account for more than 90% of human 
cancer (Hanahan and Weinberg, 2000). 
Cancer cells are defined by traits such as loss of contact inhibition and self 
sufficiency in growth. There are varieties of defects in individual cells caused either by 
genetic alterations or misregulation of signaling pathways. The origin of cancer cells can 
be traced to a single primary tumor which has gone through heritable changes enables 
them to outgrow their neighbors. The primary tumor is called benign as they can still be 
cured by removing the mass surgically whereas aggressive and invasive form known as 
malignant tumor have acquired the ability to form secondary tumors at distant micro-
environment. The malignant tumors can invade surrounding tissues, enter the 
bloodstream or lymphatic vessels and result into cell metastasis. The progression of 
primary tumor to metastatic tumor requires multiple steps through a process known as 
epithelial-mesenchymal-transition (EMT) (Fig.1) (Kalluri and Weinberg, 2009).   
 
 
 
 
 
 
 
 
 
 
Fig.1. Stages of cancer progression from normal epithelium to invasive 
carcinoma. Normal epithelium loses contact inhibition and growth factor dependency 
to form primary epithelial cencer cells. The cells follow epithelial-mesenchymal-
transition (EMT) to acquire invasive potential, angiogenic properties and enables cells 
to enter the blood circulation. The exit of these cells at remote site followed by 
mesenchymal-epithelial-transition (MET) results in metastatic tumor progression.    
Epithelial-Mesenchymal-Transition (EMT) 
EMT is a process during which an epithelial cell (polarized cell with cell-cell and 
cell-extracellular matrix interactions) undergoes multiple biochemical changes to acquire 
mesenchymal phenotype. During this process, cells have acquired characteristics like 
cellular migration and cell invasion and the cells become resistant to apoptosis which 
allow them to survive in metastatic secondary attachment site. EMT is a natural 
phenomenon in certain cases such as implantation, embryo formation and organ 
development as well as in wound healing, tissue regeneration, and organ fibrosis.  During 
cancer progression, EMT brings out the life-threatening changes resulting into secondary 
carcinoma from the primary malignant cancer cells. Based on the type of changes and 
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tissues involved, three types of EMT have been characterized (Kalluri and Weinberg, 
2009). 
Type 1 EMT: This type of EMT has been described during implantation, embryo 
formation, and organ development. During this process, diverse cell types are generated 
which shares common mesenchymal features. The process begins with gastrulation 
where fertilized eggs develop into three germ layers. The epiblast layer exhibits apical-
basal polarity as a result of E-cadherin expression. The mesenchymal transition activates 
wnt signaling pathways, which in turn upregulates EMT genes such as snail, well 
characterized for its role in E-cadherin repression. The EMT is completed by a process 
called MET (mesenchymal-epithelial-transition) which is involved in generating secondary 
epithelia (Vicovac and Aplin, 1996).  
Type 2 EMT: This type of EMT process has been described during wound healing, 
tissue regeneration, and organ fibrosis. The repair-associated events generate fibroblast 
and other related cells and the tissue is reconstructed following trauma and inflammatory 
injury. This event has also been described during kidney, liver, lung, and intestine 
regeneration. The extra-cellular matrix proteins such as collagen, laminins and vimentin 
contribute to this process efficiently (Rastaldi et al., 2002). 
Type 3 EMT:  The type 3 EMT describes the event during tumor progression and 
metastasis. The genetic/epigenetic changes affect oncogene and tumor suppressors that 
result in neoplastic cell growth and favor clonal outgrowth for the development of localized 
tumors. These localized tumors are characterized by increased proliferation and 
angiogenesis (formation of networks of blood vessels). During EMT, a multi-step 
invasiveness occurs through basement membrane which results in metastatic 
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dissemination. The EMT cells start expressing mesenchymal proteins such as vimentin 
and desmin and the process includes intravasation, transport through circulation, 
extravasation, formation of micro-metastases and colonization. It is also believed that the 
genetic/epigenetic changes are more responsive to EMT-inducing heterotypic signal 
originated in the tumor mediated stroma. EMT also inhibits oncogene-mediated 
senescence to cause aggressive dissemination. The EMT signals originated from stroma 
include growth factors such as HGF, EGF, PDGF, and TGF-beta etc. These signals 
activate EMT genes such as snail, slug, ZEB1, and Twist etc which in turn promote 
complex EMT reprogramming. The reprogramming activates signaling pathways including 
ERK, MAPK, PI3K as well as receptor proteins promoting adhesion to extracellular 
proteins (integrins). The reprogramming of these cells results in disruption of adherens 
junctions and promotes cell-ECM adhesions by integrins (Thiery, 2002). For the purpose 
of the present review, cancer relevant EMT will be referred to as general EMT.  
 
 
 
 
 
 
 
 
 
Fig.2. Epithelial-mesenchymal-transition (EMT). EMT helps tumor cells to 
acquire malignant features with increased mobility/invasiveness as well as 
resistance to chemotherapeutics and anoikis. In many cases, these cells are 
resistant to senescence. 
The tumors can originate from various heritable cellular defects. The affected cells 
can be reprogrammed for epithelial-mesenchymal-transition (EMT) by various factors. 
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The cell characteristics during EMT show common features i.e. they lose epithelial nature 
(loss of E-cadherin) and start behaving like mesenchymal cells (expression of N-cadherin, 
fibronectin, and vimentin etc). 
The common features for EMT cells include (i) increased invasiveness/motility, (ii) 
acquisition of stem-cell features, (iii) resistance to chemotherapeutics, and (iv) resistance 
to anoikis (Fig. 2) (Weinberg, 2008).  
Increased invasiveness/motility: Cell motility/invasiveness is a critical component 
of EMT. The mesenchymal cells have increased motility/invasiveness properties, as a 
result of integrin-mediated responses to the extracellular matrix (Keely et al., 1997). This 
event correlates with actin cytoskeleton reorganization mediated by small GTPases such 
as Cdc42 and Rac. The migration occurs through a well identified processes including (a) 
development of polarized cell projections, (b) focal adhesions mediated projection 
stabilization (c) cell contraction, and (d) forward cell migration as a result of rear end 
detachment. Various growth factors (EGF), cytoskeletal (spectrin), integrins (integrin and 
FAK), proteases (MMPs, calpains etc.), and signaling (ERK, MEK etc.) components 
collaborate for this process. 
Acquisition of stem-cell features: During EMT, various pleiotropically acting 
transcription factors overexpress, which are otherwise known to play critical roles in 
embryogenesis, develop malignant traits. These transcription factors (Twist, Snail, Slug, 
goosecoid, FoxC2, ZEB1, and ZEB2/Sip1 etc) can reprogram to a less differentiated cell 
with self-renewal properties. In experimental set up, these EMT-transcription factors are 
capable of inducing expression of other members of this group (Mani et al., 2008).  
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Resistance to chemotherapeutics: There is increasing evidence that the cancer 
cells which have undergone EMT, show increased resistance to apoptosis and 
chemotherapeutics drugs. Snail overexpression confers resistant to TNF-alpha induced 
apoptosis whereas slug null mutant mice in contrast show an increased sensitivity to the 
death induced by gamma-irradiation (Vega et al., 2004), (Inoue et al., 2002) and (Perez-
Losada et al., 2003). TGF-beta and other family members promote EMT by inducing 
snail/slug expression in hepatocytes, epithelial and mesothelial cells. Various tumor types 
have been reported to acquire Paclitaxel (a taxol group of drug, known to target 
microtubules and can arrest cells in mitosis) resistance as a result of Twist1 gene 
amplification (Wang et al., 2004). The breast cancer cells systematically selected for 
highly invasive phenotype promote Paclitaxel resistance by the virtue of Twist1 mediated 
transcriptional reprogramming (Cheng G.Z. et al., 2007). The DNA damaging drug 
Adriamycin, frequently used in cancer therapeutics, is known to function through p53 
mediated pathway (Saito et al., 2003). Adriamycin treatment resistant breast cancer and 
ovarian cancer cells displayed EMT features and upregulated Twist1, correlates with 
multidrug resistance and increased invasive potential (Li et al., 2009). A panel of 
pancreatic cancer cells such as AsPC-1, PANC-1 etc. showed resistance to various 
chemotherapeutic drugs such as Genicitabine, Cisplatin etc. through induction of ZEB1 
dependent EMT reprogramming (Arumugam et al., 2009). The resistance to apoptotic 
and chemotherapeutic drugs result in therapy failure and reduced survival for cancer 
patients. For the better therapeutic approach, it is essential to understand the molecular 
mechanisms underlying drug resistance. The drugs reversing EMT used in combination 
with existing therapeutic agents could be better therapeutic interventions. 
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Resistance to anoikis: Anoikis (or homelessness in Greek) is a subtype of 
apoptosis which is inhibited by cell-extracellular matrix interaction (Frisch and Francis, 
1994). This safeguard mechanism is the basic feature of normal epithelial cells, which in 
turn suppresses tumorigenic/metastatic behavior (Fig.3). Anoikis helps maintain the 
homeostasis in tissues with high turnover rate such as the gastrointestinal tract, 
mammary and prostate glands. Any misregulation during the anoikis process could 
increase colonizing property and formation of secondary metastatic tumors. The EMT 
cells acquire the characteristics of mesenchymal cells and they frequently lose epithelial 
markers. Mesenchymal cells by nature are resistant to anoikis as they do not need 
extracellular matrix for survival. Anoikis is strictly a sub-set of apoptosis. To understand 
the process of anoikis better, we should review apoptosis and its contributors which are 
also critical for anoikis.  
 
 
 
 
 
 
 
 
 
 
Fig.3. Anoikis suppresses metastasis. Loss of cell-extracellular matrix interaction 
induces apoptosis, known as anoikis. Inhibition of anoikis promotes metastasis during 
tumor progression. 
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Apoptosis  
Apoptosis is a descriptive name given to the process of programmed cell death in 
eukaryotes. Apoptotic cell suicide is a fundamentally important biological process that is 
required to maintain the integrity and homeostasis of multi-cellular organisms. The 
apoptotic response in cells can be activated by several physiological conditions such as 
DNA damage induced by cytotoxic stress, lack of growth factor receptor (GFR) signaling, 
binding of death ligands such as FasL and TNF to the respective death receptors (DR) 
and loss of cellular contact with extra-cellular matrix (anoikis). All the different pathways 
share many common components. During apoptosis, the cell activates an intrinsic suicide 
mechanisms which systematically traces the cell, surface membrane begins to bleb, cell 
expresses prophagocytic signals, cells start to shrink, and severs contact with its 
neighbors. The nucleus shows condensed and cleaved chromatin (ensuring genetic 
death of the affected cell) and eventually the whole cell fragments are engulfed into the 
membrane bound vesicles that are rapidly ingested by neighboring cells. The apoptotic 
process is extremely rapid (typically a few minutes to few hours), and the apoptotic debris 
is cleared away with similar rapidity. Programmed cell death occurs in most animal 
tissues to eliminate harmful cells or those produced in excess (Fraser and Evan, 1996) 
(Enari et al., 1995). Apoptotic signals are generally characterized by two major pathways: 
Extrinsic or Intrinsic. The extrinsic pathways include activation of death receptors such as 
TNF receptor or FAS by their ligands such as TNF or FasL. When three death ligands 
bind to their respective homotrimeric receptors, the receptor death domains cluster to 
recruit adaptor proteins such as FADD (FAS-associated Death Domain protein) and 
TRADD (TNFR1-associated Death Domain protein). These adaptor proteins have death 
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domains and in turn recruit the initiator caspases such as caspase-8 through death 
effector domain (DED). The initiator caspases in turn activates the effector caspases such 
as caspase-3/-7 (Ashkenazi and Dixit, 1998). The cellular stress induced intrinsic pathway 
is mediated by Bcl-2 (CED-9 homolog) family members. The interplay of Bcl-2 family 
member proteins regulates the mitochondrial integrity and the apoptosis process 
promotes release of mitochondrial components required for activating terminal caspases. 
Bcl-2 family members can either be pro-apoptotic or anti-apoptotic. They possess either 
one of the four conserved motifs known as the Bcl-2 homology (BH) domains, BH1, BH2, 
BH3 and BH4. The distinguishing feature of this family is the ability to form homodimers 
and heterodimers. In normal physiological condition, the anti-apoptotic Bcl-2 family 
proteins (e.g. Bcl-2 and Bcl-xl etc.) remain localized to the mitochondria to keep the 
mitochondria intact. Under cytotoxic stress, the change in physiological status is sensed 
by pro-apoptotic Bcl-2 family proteins (Bax, Bak, and Bok etc.), which in turn titrates out 
the anti-apoptotic Bcl-2 family member proteins. The activated pro-apoptotic Bcl-2 family 
proteins localize to the mitochondrial membrane, leading to mitochondrial 
permeabilization that results in generation of reactive oxygen species, loss of ATP 
production, release of cytochrome c and the apoptosis inducing factor (AIF). One of the 
released proteins, cytochrome c forms a complex with Apaf-1 (CED-4 homolog), which in 
turn activates the initiator caspase, caspase-9 (Adams and Cory, 1998). Caspase-2 has 
also been shown to be required for the pre-mitochondrial permeabilization (Lassus et al., 
2002). Once the initiator caspases are activated, they process and activate the 
downstream caspases such as caspase-3, -6 and -7. The activation of terminal caspases 
acts as point of no return for the ongoing apoptotic event. Extrinsic pathway also activates 
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mitochondrial permeabilization through activation of caspase-8, which results in cleavage 
of Bid into tBid, in turn stimulates the release of cytochrome c from the mitochondria and 
amplification of caspase cascade (Boatright and Salvesen, 2003). In anoikis, extrinsic and 
intrinsic pathway members also contribute by a process initiated by integrins and other 
adhesion molecules, cytoskeletal re-organization with various signaling and 
transcriptional reprogramming.  
Anoikis  
As mentioned previously, anoikis is induced by cell-extracellular matrix dissociation 
or engagement of inappropriate matrix. By definition, anoikis is the result of interplay 
between cell-matrix interactions and is therefore, regulated by core apoptotic molecules, 
cell-matrix and cell-cell adhesion molecules (such as integrins, non-integrins and 
cadherins) as well as various receptor kinases, Rho GTPases and nuclear factors. 
Bcl-2 family members: The interplay between pro-apoptotic and anti-apoptotic Bcl-
2 family proteins regulate the intrinsic pathway of apoptosis through the control of 
mitochondrial integrity. The preliminary characterization of anoikis indicated that the 
MDCK, HaCat and E1A reverse transformed HT1080 cells overexpressing Bcl-2 resisted 
anoikis (Frisch and Francis, 1994). Other Bcl-2 family members such as Bmf (Bcl-2 
modifying factor), Bim, Bad and Mcl-1 have also been implicated in the regulation of 
anoikis response. The proapoptotic BH3-only protein Bmf, interacts with dynein light 
chain-2, a component of myosin V complex, and remain sequestered until anoikis 
induction or treatment of cytochalasin D treatment allows Bmf to translocate and titrate 
out Bcl-2 (Puthalakath et al., 2001). In 3-D morphogenesis assay, Bmf is reported to be 
required for lumen formation (a process similar to anoikis) (Schmelzle et al., 2007). 
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Similarly, the pro-apoptotic BH3-only protein Bim interacts with cytoplasmic dynein light 
chain (DLC1), a component of microtubule associated dynein motor complex and remain 
sequestered until the apoptotic stimuli (Puthalakath et al., 2001). The co-ordinated 
regulations of Bim by integrins and EGFR have been implicated in suppressing anoikis. 
Integrins and EGFR activate ERK/MAPK pathway, leading to Bim phosphorylation, and 
its degradation. Bim expression is found to be induced in cells detached from extra-
cellular matrix (Biswas and Greene, 2002; Ley et al., 2004; Reginato et al., 2003). 
Interestingly, the pro-anoikis signaling cascade involving JNKs have been reported to 
phosphorylate Bim and Bmf, affecting their associations with dynein or myosin V 
respectively, and resulting in cytochrome c release. This suggests a mechanistic 
connection between JNKs and downstream events that lead to anoikis (Lei and Davis, 
2003). Another anti-apoptotic Bcl-2 family member, Mcl-1 is shown to overexpress in 
melanomas have been shown to overexpress in melanomas. The overexpression of Mcl-
1 is the result of mutated B-RAF (50-70% melanomas) and activated MEK/ERK pathway. 
The transient knockdown of Mcl-1 (using RNA interference) renders mutant B-RAF 
melanoma cells sensitive to anoikis. This observation suggests that the BH3 mimetic 
compounds disrupting fibronectin-integrin signaling could be used for therapeutic 
approaches (Boisvert-Adamo et al., 2009). 
Death Receptor Signaling Pathway: Death Receptor or extrinsic pathway is critical 
for apoptosis. At present, there is very limited evidence suggesting the involvement of this 
pathway in anoikis. The expression of dominant negative form of FADD suppressed 
anoikis by blocking caspase-8 recruitment at the DISC (death-inducing signaling 
complex) (Frisch, 1999; Rytomaa et al., 1999). Although, these data support the 
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involvement of extrinsic pathway, the direct involvement of death receptor is yet to be 
demonstrated. The extrinsic pathway involvement didn’t require external ligand activation 
and soluble extracellular domains of Fas, TNF-alpha receptor and death receptor 5 
(DR5), which would act as dominant negative form for receptor activation, failed to inhibit 
anoikis (Rytomaa et al., 1999). The induction of anoikis was suppressed by expression of 
Bcl-2, suggesting that the caspase-8 activation was result of an activated intrinsic 
apoptotic pathway. During 3-D morphogenesis assay, the tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL) was found to be up-regulated, but dominant negative 
forms of FADD or TRAIL didn’t rescue the luminal clearing during the early stages of acini 
clearing (Mills et al., 2004). In contrary, anoikis induced in endothelial cells resulted in 
overexpression of Fas and Fas-L and massive downregulation of Fas pathway inhibitor, 
FLICE inhibitory protein (FLIP) indicates the involvement of extrinsic pathway (Aoudjit and 
Vuori, 2001). At present, it is believed that death receptor pathway could be the result of 
positive feed-back mechanism, secondary to mitochondrial permeabilization, which in part 
is supported by the Bcl-2 and Bcl-xL mediated inhibition of caspase-8 activation 
(Grossmann, 2002).  
Integrins dependent survival pathways: Integrins are the cell receptors known to 
link cells to basement membrane through interaction with extracellular matrix proteins 
such as fibronectin, collagen and laminin. Integrins function as the integrators of the 
extracellular matrix and cytoskeleton. Integrins are a large family of cell surface receptors 
expressed from sponges to mammals. They are combination of two subunits, alpha and 
beta. There are 8 known beta subunits which can assort with 18 different alpha subunits 
to form 24 distinct integrins. All integrins have their own binding specificity and signaling 
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properties. Most of the integrins recognize several extracellular matrix proteins with 
variable specificity. They are generally characterized on the basis of evolutionary 
relationships, binding specificities and restricted expression. Upon binding to extracellular 
matrix, integrins become clustered at cell membrane and associate with the cytoskeleton 
and signaling complexes that promote the actin (or cytokeratin) assembly. The integrins 
attachment to extracellular matrix provides the survival signal to the cell which in turn 
activates the signaling pathway for cell proliferation and differentiation (Frisch and 
Ruoslahti, 1997). Integrin-extracellular signaling has been shown to play key roles in 
development, immune responses, leukocyte traffic, hemostasis, and cancer. They are 
central to many genetic and auto-immune diseases. By definition, anoikis is a form of 
apoptosis induced by loss of cell-extracellular matrix interaction or cell interaction with 
inappropriate matrix. Anoikis can be mimicked intracellularly by cell adhesion signaling 
pathway interference such as overexpression of unliganded, dominant negative form of 
integrins, perturbation of actin cytoskeleton and interfering integrin-extracellular 
interaction by RGD (arginine-glycine-aspartate motif of extracellular matrix proteins, 
required for integrins binding) peptide. The integrins and their interacting partners, 
involved in cell signaling, cytoskeleton organization and cell migration have been 
demonstrated for their role in anoikis regulation. The ligands require specific integrins for 
survival signaling as surfaces coated with fibronectin and anti-beta2 integrin compared to 
polylysine protected endothelial cells (Meredith et al., 1993). Similarly, mammary 
epithelial cells are also protected by cell basement membrane compared to collagen and 
fibronectin matrices which failed to provide the protection (Boudreau et al., 1995). Other 
reports also suggested that the failure of integrin mediated protection was a result of 
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inappropriate signaling rather than ligand attachment to the integrins (Howlett et al., 
1995). The integrin molecules differ in their ability to suppress anoikis in a single cell type 
and alternatively, tumor cells express aberrant integrin types (Juliano and Varner, 1993). 
The integrin-mediated survival is the result of activation of signaling pathways which 
otherwise can be aberrant in tumor cells.          
The integrin-extracellular matrix association results in clustering and recruitment of 
various adaptor proteins which in turn connect with the cytoskeleton, cytoplasmic kinases 
and transmembrane growth factor receptors. The cytoskeletal proteins talin and paxillin 
bind to cytoplasmic tail of integrin beta-subunits, resulting in recruitment and 
autoactivation of focal adhesion kinase (FAK) by phosphorylation at Tyr397. This 
phosphorylation creates a binding site for src homology domain 2 (SH2) of Src or Fyn. 
The Src kinases in turn phosphorylate and activate various focal adhesion components 
such as cytoskeletal protein paxillin, tensin and the docking protein p130CAS, which 
recruits other adaptor proteins Crk and Nck. FAK is overexpressed in many tumor types 
(breast, colon, lung and squamous cell carcinomas). Another kinase from focal adhesion 
complex, ILK (integrin linked kinase) has also been reported for its role in integrin 
signaling. The role of ILK was attributed to its hyperactivity in cells with aberrantly 
activated phosphatidyl inositol (PI)-3-kinase or dysfunction of the tumor suppressor 
PTEN, correlated with ILK activation by phospholipids (Wu et al., 2001). ILK expression 
also increased in prostatic adenocarcinoma in stage dependent manner (Graff et al., 
2001). ILK dependent Akt/PKB activation may be a major mechanism of anoikis 
suppression. ILK activity increases upon cell adhesion to matrix and decreases upon cell-
extracellular matrix dissociation (Attwell et al., 2000). Recently, ILK has also been 
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demonstrated for preventing anoikis in human mesenchymal stem cells (Benoit et al., 
2007).        
Integrin signaling can activate FAK and suppress anoikis (Frisch et al., 1996). The 
activated form of FAK protects cells from anoikis through activation of extracellular signal 
regulated protein kinases (ERKs) pathway by activating ras as well as promoting 
enzymatic activity of phosphatidyl-inositol-3’-phosphate kinase (PI3K) by p85 interaction. 
The ERK pathway in turn inactivates pro-apoptotic Bcl-2 family protein BAD 
(phosphorylation by ERK target kinase, Rsk), caspase 9 and transcription factors which 
induce c-fos and cyclin D1 expression (Abbi and Guan, 2002).  
FAK is also shown to suppress anoikis by interaction with cytoskeletal protein 
paxillin and death domain containing kinase receptor interacting protein (RIP1). Paxillin 
binding to FAK activates the pro-survival mitogen activated protein kinase (MAPK) 
signaling pathway. A focal adhesion and adheren junction protein vinculin interacts with 
the leucine-rich repeat region (LD motifs) of paxillin and interfere with the FAK interaction. 
Vinculin-deficient cells are resistant to anoikis and this defect can be restored by re-
expression of the paxillin interacting carboxy-terminal tail of vinculin (Subauste et al., 
2004). The vinculin-mediated interference of FAK-paxillin interaction negatively regulates 
ERK activation and restores caspase 9 activity, suggesting a novel mechanism for the 
regulation of FAK-mediated cell survival by a cytoskeletal component. Vinculin is 
downregulated in highly metastatic tumor cells and its re-expression has previously been 
shown to suppress cancer cell motility and tumor metastasis (Rodriguez Fernandez et al., 
1993). The inhibition of FAK phosphorylation (by kinase inhibitor staurosporine) promoted  
its degradation and RIP1-dependent apoptosis (Kurenova et al., 2004). RIP1, interacting 
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partner for death domain proteins FADD and TRADD, is a well characterized protein for 
its role in death receptor signaling pathway by either activating NF-kB survival pathway or 
caspase 8 mediated pro-apoptotic pathway (Lin et al., 1999). The dominant negative form 
(carboxy-terminal domain) of FAK induces apoptosis which is attenuated by loss of RIP1. 
This study also demonstrated that RIP1-null mouse embryo fibroblast or the transient 
knockdown of RIP1 resulted in anoikis resistance (Kurenova et al., 2004). In another 
study, loss of cell-extracellular matrix interaction or expression of dominant negative form 
of FAK resulted in mitochondrial localization of Bax which was counteracted by 
expression of PI3K or src overexpression (Gilmore et al., 2009). So, the adherent cells 
block apoptosis by impairing Bax mitochondrial localization through the combined action 
of FAK, PI3K, and Src, which might otherwise be nonfunctional during anoikis (Playford et 
al., 2008).  
The p130Cas family proteins, known to be phosphorylated by Src kinase and 
interact with the Crk family of adaptor proteins, also interact with FAK to regulate anoikis. 
The p130Cas and related protein, HEF1 (human enhancer of filamentation-1) interact 
with FAK PxxP domain. They get inactivated during the G2 to M transition, either via 
phosphorylation in case of p130Cas or caspase-mediated cleavage in case of HEF1. The 
inactivation of these proteins might lead to loss of cell adhesion, required for the onset of 
mitosis. The p130Cas and HEF1 family proteins are also cleaved by caspases during 
death receptor-induced apoptosis. HEF1 overexpression or the caspase-cleaved form of 
p130Cas has been shown to induce apoptosis (Law et al., 2000; Wei et al., 2004). FAK, 
in part, regulates cell survival through binding to p130Cas and/or HEF1 — either 
sequestering them or altering their interactions with downstream effector proteins. 
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Constitutively hyperphosphorylated forms of p130Cas have been detected in lung 
adenocarcinoma cells, perhaps permitting these cells to evade anoikis (Wei et al., 2002).  
Src phosphorylation of p130cas allows it to interact with the adaptor molecule CRK 
through the SH2 domain. Interestingly, the related CRKII protein is required for 
mitochondrial cytochrome c release and caspase activation in Xenopus extracts (Smith et 
al., 2002). CRKII was found to interact with the tyrosine kinase WEE1, an inhibitor of 
cdc2/cyclinB activity, in the nucleus. WEE1 protein was also critical for apoptosis 
induction in this system, as was the interaction of CRKII with WEE1, but not the kinase 
activity of WEE1 itself. The second SH3 domain of CRKII interacts with the nuclear export 
protein CRM1, and mutation of this domain enhances the apoptotic effect of the CRKII 
protein, presumably by causing its retention in the nucleus. These results indicate that 
FAK might promote survival, in part, by sequestering CRK in the cytoplasm, thereby 
preventing its pro-apoptotic, WEE1-dependent function. 
Cas and Crk may also play important roles in bypassing anoikis in normal epithelial 
cells during cell migration processes, such as those involved in wound healing. Factors 
that promote cell migration, such as EGF and hepatocyte growth factor (HGF), confer 
resistance to anoikis (Miller et al., 2003). Cos-7 fibroblasts embedded in collagen gels 
were found to undergo anoikis unless migration stimulated EGF or insulin. However, 
growth factor independent survival in this system was conferred by cotransfection of both 
CAS and CRK. Overexpression of CRK or hyperphosphorylation of p130cas has been 
correlated with aggressiveness of lung adenocarcinoma. So CRK, in addition to its pro-
apoptotic behavior described above, might mediate cell survival during cell migration. 
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CAS, CRK or other cell migration-related molecules might make useful therapeutic 
targets for overcoming anoikis resistance or preventing metastasis.                               
Rac Signaling in survival pathways: Cell motility generally correlates with survival 
pathway and pathways affecting these involve Rac family of GTPases. Rac is critical for 
actin polymerization at the leading edge of migrating tumor cells (supports lamellopodia 
formation for movement) as well as activation of PAKs, which in turn contribute to ERK 
activation (Burridge and Wennerberg, 2004).  
The small GTP-binding GTPases superfamily exist in cells as either the inactive 
guanosine diphosphate (GDP) bound form or the active GTP-bound form. The GTP-
bound form in turn is regulated positively by nucleotide exchange factors or negatively by 
GTPase activating protein. The GTPases such as Rac1, Cdc42, and nucleotide exchange 
factor Tiam1 have been shown to confer resistance to anoikis. Rac is activated either by 
integrin signaling following cell-matrix adhesion or by stimulation by motility factors. FAK 
also contributes to these pathways. Rac activation results in protecting cells through 
activation of ERK and Akt (Coniglio et al., 2001; Zahir et al., 2003). In a different context, 
alpha6beta4 intergrin mediated cell survival, Rac protected cells through activation of NF-
kB pathway (Zahir et al., 2003). 
Rac is a known activator for PAK, supporting various pathways of cell survival. 
PAK1 phosphorylates Bad, promoting the release of Bcl-2 and activation of anti-apoptotic 
pathways. PAK4 also phosphorylates Bad and has been shown to promote anchorage 
independent growth (Gnesutta et al., 2001; Qu et al., 2001; Schurmann et al., 2000).   
Non-integrin cell adhesion signaling in cell survival: Various non-integrin cell 
adhesion molecules have been shown to affect anoikis sensitivity and variably expressed 
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during tumor progression and metastasis. These molecules include hemophilic cell 
adhesion molecules such as E-cadherin, PECAM, CEA, and CEACAM, hyaluronan 
receptor CD44 and neurotrophic factor binding receptor with tyrosine kinase activity, TrkB 
etc. 
E-cadherin: During the early characterization of anoikis in MDCK cells, cell-cell 
interaction was reported to promote anoikis sensitivity whereas cells in sparse culture had 
dramatically reduced anoikis sensitivity (Frisch and Francis, 1994). This observation 
suggested that the cell-cell interactions sensitized cells to anoikis whereas their 
breakdown might contribute to loss of epithelial polarity and development of anoikis 
resistance. This observation has been supported by various experimental evidences that 
either loss of E-cadherin and/or cell polarity can make cells resistant to anoikis and 
promote tumor progression. E-cadherin is a cell adhesion molecule, which is required for 
maintenance of epithelial cell integrity by homophilic cell-cell interactions and formation of 
adherens junctions. E-cadherin controls the formation of catenin complexes to link actin 
and microtubule cytoskeleton (Perez-Moreno et al., 2003). In cancer, E-cadherin is 
frequently lost either through genetic or epigenetic mechanisms and promotes epithelial-
mesenchymal-transition in numerous malignancies. The targeted knockdown of E-
cadherin gene in mouse mammary tumor model or the stable knockdown of E-cadherin in 
mammary epithelial cells promoted metastasis (Derksen et al., 2006; Onder et al., 2008)  
In later case, loss of E-cadherin results in “classic” EMT phenotype compared to earlier 
case suggesting the effect of cell type and epi (genetic) constitution. Incidentally, both of 
these cells were resistant to anoikis, further confirming that the presence of E-cadherin 
and resulting adherens junction are required for anoikis response in epithelial cells. In 
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epithelial MDCK cells, Ca2+ dependent cell aggregation enhanced anoikis and 
surprisingly, the apoptotic cells in suspension cultures were mainly in single cells (Emoto, 
2008). In enterocytes, early loss of E-cadherin in suspended cells from adherens 
junctions was required for onset of anoikis (Fouquet et al., 2004). The E-cadherin 
dismantling in enterocytes was a result of EGFR activation (Lugo-Martinez et al., 2009). 
The universality of anoikis mechanism in enterocytes is yet to be confirmed. The 
mammary epithelial cells, MDCK, and enterocytes anoikis data suggest that E-cadherin is 
required for sensitizing epithelial cells for anoikis and during suspension, apoptotic cells 
get free from E-cadherin mediated cell-cell aggregation. Alternatively, E-cadherin 
mediated cell aggregates leads to intracellular signaling, which in turn protect cells from 
anoikis as reported in normal tubular cells and squamous cell carcinoma (Zhang et al., 
2004; Zhang et al., 2008). Apart from controlling adherens junction formation, E-cadherin 
also sequesters beta-catenin in cytoplasm and suppresses pro-oncogenic wnt signaling 
pathway. Loss of E-cadherin also reprograms cells for EMT by over-expressing EMT 
genes such as Twist and ZEB1. Interestingly, loss of E-cadherin mediated anoikis 
resistance can be partially reversed by downregulation of either Beta-catenin or Twist, 
which also suppressed the lung metastasis (Onder et al., 2008). Re-expression of E-
cadherin can restore apoptosis sensitivity in EMT cells by sequestering beta-catenin in 
cytoplasm and suppressing its pro-tumorigenic transcriptional activity (Stockinger et al., 
2001).    
CD44: CD44 is an extracellular and cell-surface-associated glycosaminoglycan, 
which is a receptor for hyaluronan that is overproduced by many tumor types (Knudson, 
1996). CD44's cytoplasmic domain is linked to the ezrin-radixin-moesin and ankyrin 
 
 
20 
proteins that in turn bridge the actin cytoskeleton to the membrane (Ponta et al., 2003; 
Toole, 2004). It acts as a co-receptor for c-ErbB1–3, c-Met and other oncogenic 
receptors. Certain CD44 splice variants are overexpressed in various tumor types such 
as colorectal carcinoma and mammary carcinoma. The disruption of CD44-mediated cell 
adhesion to hyaluronan by the use of soluble, truncated CD44 receptors induces 
apoptosis in mammary carcinoma cells (Yu et al., 1997). Selection of human mammary 
tumor cells for those with the highest metastatic potential yielded a subpopulation of cells 
that overexpressed CD44, underscoring the functional importance of this protein in 
metastasis (Al-Hajj et al., 2003). CD44 variants exert a powerful cell survival effect with 
respect to various apoptotic stimuli, including DNA damaging agents and anti-integrin 
antibodies (Bates et al., 2001; Bates et al., 1998). Recently, CD44 has established as 
cancer stem cell marker and shown to overexpress in highly anoikis resistant cells which 
have undergone epithelial-mesenchymal-transition (Mani et al., 2008). The exact 
mechanism of CD44 in promoting cancer stem cells is unknown.       
PECAM-1: PECAM-1 is a 130 kDa immunoglobulin-domain protein that mediates 
homophilic cell adhesion at the surface of leukocytes, platelets and endothelial cells; it is 
involved in transendothelial migration of leukocytes and angiogenesis (Newman, 1997). 
Interaction between PECAM-1 on apposing cells has been shown to protect against a 
diversity of apoptotic stimuli, including serum-deprivation, gamma-irradiation, UV 
irradiation and staurosporine (Gao et al., 2003). Interestingly, transfected PECAM-1 
protected 293 human embryonic kidney cells from apoptosis induced by BAX expression 
and did not inhibit the translocation of BAX from the cytosol to the mitochondria, but 
inhibited the cytochrome c release. Since BAX is important for the induction of apoptosis 
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and therefore anoikis, it will be important to learn more about the anti-apoptotic 
mechanisms of PECAM-1, which have also been shown to involve interaction with the 
protein tyrosine phosphatase SHP-2 (Gilmore et al., 2000). Cell aggregations have been 
reported to suppress anoikis and promote survival. The suspended cultures of high cell 
density cultures promoted PECAM tyrosine phosphorylation. The cell survival depended 
on a novel PECAM interacting partner Pyk2 (Proline-rich tyrosine kinase 2), a member of 
FAK family member known for its role in adhesion and role in cytoskeletal structure 
regulation (Zhang et al.).     
CEA and CEACAM: Carcinoembryonic antigen (CEA) and its relative, 
carcinoembryonic antigen-related cell adhesion molecule-6 (CEACAM-6), are membrane-
bound, GPI-linked, immunoglobulin superfamily proteins that are overexpressed by a 
number of different carcinoma cell types including colon, breast, and lung etc. 
Overexpressed CEA has been shown to contribute to the anoikis-resistance of colon 
carcinoma cells (Ilantzis et al., 2002). Recently, the siRNA-mediated reduction of 
CEACAM-6 levels in pancreatic carcinoma cell lines was shown to promote anoikis and to 
inhibit metastasis of tumor cells in a nude mouse orthotopic xenograft model. The 
mechanism of anoikis-resistance by overexpressed CEA or CEACAM was considered by 
the involvement of Src-family kinases, modulation of a5b1 integrin function, or steric 
interference with the assembly of cell-cell junctional complexes. Recent studies have 
indicated that CEA interacts and suppresses pro-apoptotic activity of death receptor 
TRAIL-R1 (DR5) and its caspase-8 activation pathway in colorectal cancer (Samara et 
al., 2007). Another report using the overexpression of either CEA and/or a chimeric 
protein consisting of the NCAM extracellular domain attached to the CEA-GPI anchor 
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activated PI3K/AKT pathway and inhibited caspase-9 activation, suggesting the 
involvement of intrinsic pathway (Camacho-Leal and Stanners, 2008). The universality of 
these studies is yet to be verified.       
TrkB: The anti-apoptotic activity of the receptor tyrosine kinase TrkB, which binds 
the neurotrophin brain-derived neurotrophic factor (BDNF), has been well studied for 
many years by developmental neuroscientists (Davey and Davies, 1998; Jaboin et al., 
2002). TrkB however is expressed by a variety of other cell types and its overexpression 
has been documented in pancreatic carcinoma, prostate carcinoma, Wilms tumor and 
neuroblastoma. TrkB was identified as an anoikis suppressor in a screen for genes that 
conferred epithelial cells with the ability to survive in suspension. TrkB expression did not 
however suppress serum withdrawal-induced apoptosis, indicating its specific activity in 
inhibiting apoptosis only under certain conditions. Its overexpression also caused several 
curious effects, including diminished cell–cell interactions of cells on two-dimensional 
culture, the formation of cell spheroids in suspended cell populations and Akt activation. 
The activated Akt has previously been shown to be involved in suppressing anoikis. 
Overexpressed TrkB also induced metastatic behavior of rat intestinal cells (Douma et al., 
2004). The structural and functional characterization of TrkB indicated its kinase domain 
and not the extracellular adhesion motifs promoted anoikis resistance, oncogenicity and 
metastasis (Geiger and Peeper, 2007). The overexpression of TrkB in presence of its 
ligand BDNF, upregulated Twist via MAP Kinase dependent signaling pathway. Twist, in 
turn upregulated Snail followed by E-cadherin repression resulting in anoikis resistance 
and metastasis (Smit et al., 2009). Several inhibitors targeting TrkA or TrkB are being 
developed for cancer therapeutics. Few of the Trk inhibitors reaching clinical trial were 
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CEP-751, CEP-701 (Cephalon) and AZ-23 (Astrazeneca). CEP-751 and CEP-701 
suppressed tumor progression in xenograft models of prostate, pancreatic, 
neuroblastoma and medulloblastoma tumors. At present, CEP-701 is in phase 2 studies. 
There are no activating mutations of TrkB reported for the cause of tumor, so these 
inhibitors could be used as chemotherapeutic adjuvant in conjunction with standard 
chemotherapeutic agents (Thiele et al., 2009).            
Nuclear Factors: Anoikis is a very immediate process. The translocation of Bax to 
mitochondria or caspase activation occurs within minutes of cell-extracellular matrix 
dissociation. Transcription factors may not contribute to the process of anoikis response. 
It is conceivable that transcription factors can reprogram cells for appropriate response 
during cell-extracellular matrix detachment. The stable expression of adenovirus E1a 
reprogrammed various human tumor cells to assume epithelial characteristics and 
sensitized them for anoikis (Frisch and Francis, 1994). Similarly various EMT inducing 
genes such as Twist, Snail, Slug, and ZEB1 etc. reprogram cells to lose epithelial 
characteristics and develop mesenchymal properties. The cells with mesenchymal 
properties are resistant to anoikis. The response to anoikis sensitivity could be 
programmed by regulation of epithelial and apoptotic genes.  
One of the transcription co-repressor known as carboxy terminal binding protein 
(CtBP), known to co-operate with various repressors such as Zeb1 and repress various 
pro-apoptotic and epithelial genes such as PERP (p53-effector related to pmp-22), p21, 
Bax, and Noxa (Chinnadurai, 2009). The mesenchymal epithelial transition ability of E1a 
is partially through inactivation of CtBP (Grooteclaes and Frisch, 2000). In mouse embryo 
fibroblasts or human tumor cells, CtBP inactivation initiates a mesenchymal to epithelial 
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transition, which upregulates epithelial specific genes such as E-cadherin. The cell types 
become dramatically more sensitive to anoikis. Recently, ZEB1 mediated metastasis by 
inhibiting stemness microRNA-203 and other microRNA (miR-200) family members and 
affecting expression of stemness gene such as polycomb repressor Bmi1 (Wellner et al., 
2009). Targeting EMT genes and inactivating them either genetically or pharmacologically 
could reprogram cells for epithelial phenotype and can be used as an approach for 
cancer therapeutics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4. Anoikis regulators. The cellular process of anoikis is regulated by many 
pathways. The pro-epithelial/pro-apoptotic including adhesion molecules, 
transcription factor, and cell death pathway promote anoikis whereas oncogenic/pro-
survival pathways suppress anoikis which include integrins, adhesion molecules, anti-
apoptotic Bcl2-family members, and oncogenic transcription factors.   
The very general overview has been summarized in fig.4. There are various other 
important advancements in the field of anoikis which may have remained overlooked in 
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this review. Understanding cellular regulations for anoikis and targeting individual 
pathways could be used as an approach for cancer therapeutics.    
ANKYRIN 
Ankyrins are a family of adaptor proteins that link the actin cytoskeleton to 
membranes through interaction with spectrin and integral membrane proteins. They are 
ubiquitously expressed intracellular proteins evolved to perform specialized functions in 
metazoans and multicellular organisms, as they are absent in yeast and plants 
(Arabidopsis thaliana and Zea mays etc.) though present in Drosophila melanogaster 
(Dank1 and Dank2) and Caenorhabditis elegans (unc44) with high level of homology with 
their vertebrate orthologues (Mohler et al., 2002; Rubtsov and Lopina, 2000, Mohler, 
2002 #164).  
Ankyrins are encoded by three different genes in vertebrates and each contains 
multiple splice variants. The ankyrin prototype ankyrin-R named for its restricted 
expression in erythrocytes but also expressed in a subset of neurons, and striated 
muscles, is encoded by Ank1 on chromosome 8p11. Ankyrin-B, known for its broad 
expression, was first characterized in brain. Ankyrin-B is encoded by Ank2 gene on 
human chromosome 4q25-27. The third ankyrin isoform ankyrin-G, named for its giant 
size and general expression pattern is encoded by Ank3 on human chromosome 10q21. 
This is also considered as epithelial ankyrin-G for its role in epithelial cell maintenance 
(Mohler et al., 2002).  
Ankyrin domains: All of the three isoforms of ankyrin have common domain 
structures. Ankyrins have three major common domains namely membrane binding 
domain (MBD) which contains ankyrin repeats (AR), spectrin binding domain (SBD), and 
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the ZU5-UPA-DD supermodule (fig.5).  The diversity in different ankyrin gene products is 
because of the variation in regulatory regions at the extreme c-terminus. The exact 
function of the regulatory region is currently unknown. The spectrin binding domain has 
been characterized as the function of its ZU5 domain and subsequent 55 amino acids 
(Mohler et al., 2004). Further characterization based on sequence homology between 
ZU5 and death domain containing proteins suggested the presence of a supermodule 
containing another ZU5 (ZU5-B), UPA (named for being conserved in unc5, PIDD and 
ankyrin) and the death domain (Wang et al., 2009).  
The membrane binding domain (MBD), known for the presence of various ankyrin 
repeats (AR), is named for interactions with multiple membrane proteins. The ankyrin 
MBD contains 24 ankyrin repeats and helps assemble the multiprotein complexes at 
specific cellular sites. This domain is involved in binding to ion channels/pumps such as 
anion exchanger isoforms (AE1, AE2, AE3), the Na+-K+-ATPase, the voltage-dependent 
Na+-channel and Na+/Ca+ exchanger; IP3 receptor and ryanodine receptor, Ca2+ release 
channels, cell adhesion molecules (CAMs) including CD44, L1 CAM family 
(L1/neurofascin/NrCAM/CHL1/NgCAM/LAD-1/neuroglian), cytoplasmic proteins such as 
tubulin and clathrin, and the guanine nucleotide exchange factor (GEF) Tiam1. These 
interactions regulate a variety of cell processes including ion homeostasis, adhesion 
functions, and protein trafficking (Mohler et al., 2002). Each ankyrin repeat (AR) is 33 
amino acids tandem repeats, forms protein-protein interaction motifs, and found in a large 
number of functionally diverse eukaryote proteins (rarely in prokaryotes), and the 
presence is hypothesized because of horizontal gene transfer. Ankyrin repeats (AR) are 
structural rather than functional motifs and are found in proteins involved in transcriptional 
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regulation such as GABP beta and NF-kappaB inhibitor IkappaB, cell-cycle regulators 
tankyrase and p53-binding protein (53BP2), cytoskeleton (ankyrins), ion transporters 
(TRP family of ion channels) and signal transducers. Each of the ankyrin repeats fold into 
a helix-loop-helix structure with a beta hairpin/loop region projecting out from the helices 
at a 90o angle. The repeats stack together to form an L-shaped structure. The crystal 
structure of ankyrin repeats suggested that they form spiral stacks, and the spectrin 
binding domain fragment interacts as an extended strand. Based on in vitro binding 
studies and the structural model, ion transporters interacts with large central cavity 
formed by spiral ankyrin repeats whereas clathrin and cell adhesion molecules associate 
through the specific regions outside this cavity (Michaely et al., 2002). The antiparallel 
alpha helices are predicted to form superhelical spiral stacks, and atomic force 
microscopic measurement suggested the reversible linear elasticity extended in multiple 
stretches and exhibited nanospring like properties. The mechanical properties in turn are 
predicted to respond to mechanical strain and generate flexibility in membrane bilayer 
plane (Lee et al., 2006).  
The central domain of ankyrin consists of spectrin binding domain (SBD) in all of 
the three ankyrin gene products. Ankyrin was first identified on the basis of spectrin 
binding in erythrocytes. Mutation in ankyrin-SBD leads to the development of several 
diseases in human and mice such as hereditary spherocytosis and reduced levels of 
axon initial segments. The interaction studies using yeast 2-hybrid identified the internal 
ZU5 domain (named for its presence in ZO1 and Unc5H1) along with 55 amino acids as 
the minimum spectrin binding domain. The ZU5 domain within spectrin binding domain is 
first among the two ZU5 domains and so, being referred to as ZU5-A. Site directed 
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mutagenesis of DAR976AAA and A1000P within ZU5-A abolished the ankyrin-spectrin 
interaction (Mohler et al., 2004). This interaction has been verified biochemically and the 
interaction ratio between ZU5 domain and 14th/15th β-spectrin was found to be 1:1 (Ipsaro 
et al., 2008). Further structural characterization revealed that the 14th spectrin repeat 
contains a conserved negatively charged patch which could account for its interaction 
with the positively charged ZU5-A domain. The ZU5-A domain contains a conserved beta 
core structure but lacks part of canonical ZU5 consensus sequence, which makes it 
structurally more appropriate for spectrin binding (Ipsaro et al., 2009).    
The recently identified ZU5-UPA-DD supermodule function is currently not well 
understood. Part of this supermodule contains the death domain (DD) which has 
previously been characterized in the context of receptor mediated apoptotic pathways. 
The death domain was first identified in TNF family receptor (i.e. TNF receptor and Fas). 
The death domains are known to homodimerize and heterodimerize with other death 
domain proteins.  The high affinity death domain proteins such as FADD, TRADD and 
RIP were identified using the yeast two-hybrid system, whereas low affinity death domain 
proteins such as nerve growth factor receptor (NGFR) and ankyrin were identified by 
sequence homology. There are two subtypes of death domains, subtype 1 includes Fas, 
TNFR1 (TNF Receptor1 or p55-R), FADD, ankyrin, RIP and TRADD whereas the subtype 
2 includes DAP Kinase, NGFR, p100 and p105 members of Rel protein family, and 
myD88. All of the death domains are predicted to have five sequential alpha helices with 
exceptions of either of one missing in different types (Feinstein et al., 1995). Function of 
the ankyrin death domain (ankDD) is not well understood. Recently, the death domain of 
ankyrin was shown to interact with Fas (yeast 2-hybrid and co-immunoprecipitation in 
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MDCK cells) and FADD (co-immunoprecipitation in MDCK cells) through their death 
domains. The site directed mutagenesis of conserved ankyrin-G R1496 abolished this 
interaction. In a mouse model of renal ischemia-reperfusion injury, the expression as well 
as interaction between ankyrin and Fas increased markedly. The MDCK cells stably 
expressing ankyrin-G, responded to Fas ligand induced apoptosis in MDCK cells. This 
was the first demonstration of ankyrin-G in regulation of cell death (Del Rio et al., 2004). 
The universality of this interaction and pathway is yet to be confirmed.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5. Ankyrin links membrane proteins to actin cytoskeleton. Ankyrin contain 
N-terminal membrane binding domain with 24 ankyrin repeats, central spectrin 
binding domain (ZU5-A and ~55 amino acids) and ZU-5b-UPA-DD supermodule. 
The membrane binding domain interacts with various membrane and cytoplasmic 
proteins and links them to actin-spectrin cytoskeleton. The function of ZU-5b-UPA-
DD supermodule is not well characterized. The c-terminal domain is unique in each 
ankyrin type but its function is yet to be characterized. 
Ankyrin-G: Ankyrin-G was first characterized in brain tissues and exhibited 
extremely high molecular sizes (480 kDa and 270 kDa). Apart from the common ankyrin 
domain structures (i.e. MBD, SBD and ZU5-UPA-DD supermodule), these variants 
contain a unique serine and threonine rich domain of more than 200 kDa, restricting 
ankyrin-G at axonal proximal segments (Kordeli et al., 1995). The ankyrin-G null (-/-) 
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mouse neurons failed to restrict the voltage-gated sodium channels (NaCh) and 
neurofascin (L1 family member of adhesion molecule) at their axon proximal segments, 
suggesting the role of ankyrin-G in specialized membrane domain assembly (Zhang and 
Bennett, 1998). The membrane binding domain of ankyrin-G interacted with neurofascin 
through conserved amino acids ser56-tyr81, and mutagenesis of FIGQY tyrosine 
(Y81H/A/E) greatly impaired the interaction. The mutation in equivalent tyrosine of L1 has 
been linked to certain cases of mental retardation, suggesting the similar role of ankyrin 
interaction modules of neurofascin (Zhang et al., 1998). The cerebellum specific ankyrin-
G knockout mouse exhibited progressive ataxia at the beginning of postnatal day P16. 
These mice also lost the Purkinje neurons, highlighting the importance of ankyrin-G in the 
assembly of normal brain tissues (Zhou et al., 1998).  Recently, ankyrin-G has been 
shown to interact with beta1 subunit of cyclic nucleotide-gated channel (CNG beta1) in 
the plasma membrane of photosensitive outer segments (OS) of rod photoreceptors. 
Ankyrin-G was critical for CNG beta1 targeting to the rod outer segments. The ankyrin-G 
knockdown in neonatal mouse retina markedly reduced CNG channels expression. The 
ankyrin interaction was attributed to the 28 amino acids at c-terminus of CNG beta1, the 
deletion previously reported in the retinitis pigmentosa patients. This observation 
highlights the critical role of ankyrin-G in CNG beta1 membrane targeting and its 
physiological relevance in photoreceptors function (Kizhatil et al., 2009).  
Ankyrin-G has been reported to be critical for epithelial membrane biogenesis. The 
ankyrin-G knockdown in human bronchial epithelial cells by small interfering RNA resulted 
in the loss of lateral plasma membrane in interphase cells. The cells also lost the post 
mitosis membrane biogenesis, although the apical/basal plasma membranes and cell 
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polarity remained unaffected. Additionally, the localization of ZO1 in tight junction and E-
cadherin/beta catenin in adherence junctions remained unaffected, whereas E-cadherin 
and Na+-K+-ATPase in lateral membrane were severely affected. The membrane 
biogenesis could be rescued by the re-expression of rat ankyrin-G (siRNA resistant). 
However, chimeric ankyrin-G containing either of ankyrin-B domains (MBD or SBD or DD) 
failed to restore ankyrin-G dependent membrane biogenesis, suggesting the pleiotropic 
requirement of all ankyrin-G domains in membrane biogenesis (Kizhatil and Bennett, 
2004). Ankyrin-G interacting ion pump Na+-K+-ATPase has been shown to lose the cell 
polarity following ischemic injury. ATP depletion resulted in duration dependent 
mislocalization of ankyrin-G and Na+-K+-ATPase without affecting their interaction in 
Madin-Darby canine kidney (MDCK) cells. Further characterization revealed that the ATP 
depletion affected ankyrin-G-spectrin interaction, which in turn correlated with ankyrin-G 
hyperphosphorylation (serine/threonine and tyrosine). This observation adds further 
complexity on ankyrin-G mediated cytoskeleton re-organization, involving post-
translational modification (Woroniecki et al., 2003). Incidentally, ankyrin phosphorylation 
has previously been reported to affect its interaction with spectrin which depended upon 
serine/threonine phosphorylation by casein kinase 2 (CK2) (Ghosh and Cox, 2001; 
Ghosh, 2002). The post-translational modification of ankyrin-G would allow rapid 
membrane and cytoskeleton reorganization depending on various physiological stimuli. 
Ankyrin-G is a known interacting partner of cell adhesion molecule E-cadherin, first 
shown in MDCK cells (Nelson et al., 1990). Recently, the physiological significance of 
ankyrin-G and E-cadherin interaction was characterized. Ankyrin-G interacted and 
accumulated E-cadherin at lateral membrane and early embryos. The beta2 spectrin and 
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ankyrin-G were required for E-cadherin lateral membrane targeting in microtubule-
dependent manner. The multi-protein complex including spectrin-ankyrin-E-cadherin in 
turn co-ordinated the membrane assembly with extracellular interactions at cell-cell 
contact site (Kizhatil et al., 2007). E-cadherin is a critical adhesion molecule known for its 
requirement in epithelial cell maintenance. Loss of E-cadherin is the preliminary step in 
losing cell polarity and acquiring epithelial-mesenchymal-transition. Based on E-cadherin 
interaction, ankyrin-G is predicted to regulate various cellular processes during epithelial 
maintenance (in presence of E-cadherin) and EMT, tumor progression and metastasis (in 
absence or nonfunctional state of E-cadherin). 
Role of Ankyrin-G in Cancer: The role of ankyrin-G is not well understood in 
cancer. The interactions with hyaluronan receptor (CD44) and nucleotide exchange factor 
(Tiam1) have highlighted a few of the roles of ankyrin in tumor progression. Especially,the 
interactions between CD44 and ankyrin have been reported in various cell types including 
T-cells, endothelial cells, breast, ovary and prostate cancer cells (Bourguignon et al., 
1998; Bourguignon et al., 1992; Kalomiris and Bourguignon, 1989; Welsh et al., 1995; 
Zhu and Bourguignon, 2000). The 15 amino acid cytoplasmic region of CD44 was 
sufficient for ankyrin interaction. The hyaluronic acid (HA) treatment induced CD44-
ankyrin interaction and enhanced cell adhesion (Lokeshwar et al., 1994). Variable 
expression of CD44 among prostate cancer cell lines was compared for invasiveness and 
tumorigenesis. The CD44 negative LNCaP cells exhibited a less malignant phenotype 
compared to aggressive tumorigenesis by PPC-1 and ALVA-31 (expressing multiple 
CD44 variants), which in turn correlated with HA-dependent ankyrin localization and cell 
adhesion (Welsh et al., 1995). The over-expression of CD44 in LNCaP cells promoted c-
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Src dependent anchorage independent growth, which in turn was dependent on the 15-aa 
ankyrin binding sequence (Zhu and Bourguignon, 1998). The ankyrin-CD44 interaction 
has also been reported to promote breast cell tumorogenesis. The highly metastatic 
breast cancer cells, Met1 (derived for transgenic mice expressing polyoma virus middle T 
oncogene), expressed CD44v3,8-10 variant with intact ankyrin interaction as reported 
with other CD44 variant and formed matrix metalloprotease-9 (MMP-9) dependent 
invadopodia (Bourguignon et al., 1998). Further characterization demonstrated the 
physical interaction between CD44v3,8-10 and RhoA GTPase and activated Rho Kinase 
(ROK). The activated ROK phosphorylates the cytoplasmic domain of CD44v3,8-10, 
enhances its interaction with ankyrin, regulates membrane ruffling and cell projections 
with increased membrane motility and tumor cell migration (Bourguignon et al., 1999). In 
metastatic breast tumor cells MDA-MB-231, CD44 interacted with TGF beta receptor. The 
HA-treatment activated the serine-threonine kinase activity of TGF beta receptor, which in 
turn phosphorylates CD44 to enhance interaction with ankyrin. The increased interaction 
correlated with increased cell migration and other tumor related activities (Bourguignon et 
al., 2002). HA-treatment also enhanced CD44 and nanog interaction in breast tumor cells 
(MCF-7 cells) and ovarian tumor cells (SK-OV-3 cells). Nanog formed a complex with 
Stat-3 and activated the transcription of Stat-3 target genes including multidrug 
transporter, MDR1. The HA-CD44 interaction induced ankyrin interaction with MDR1 to 
increase the efflux of chemotherapeutic drugs. The report of the breast and ovary cancer 
cells displaying stem cell properties and novel pathways to develop chemotherapeutic 
resistance can be targeted for cancer therapeutic pathways (Bourguignon et al., 2008).  
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The nucleotide exchange factor Tiam1 interacts with ankyrin in breast tumor cells. 
The Tiam1-ankyrin interaction in membrane projections activated Rac1, which in turn 
increased cell invasion and migration (Bourguignon et al., 2000). The CD44 and Tiam1 
mediated oncogenic signaling and tumor progression depended partially on ankyrin-G 
interaction and cytoskeletal re-organization. 
Nevertheless, there are evidences which would support ankyrin-G anti-tumorigenic 
activity. The study using mouse/human comparative translational genomics approach to 
identify a death-from-cancer signature predicting therapy failure identified an 11-gene 
signature. Ankyrin-G was one of the 3 down-regulated genes, suggesting its inverse 
correlation with cancer progression (Glinsky et al., 2005). In another study, TGF-beta 
mediated human hepatocellular carcinoma model demonstrated downregulation of 
ankyrin-G (Gotzmann et al., 2006). The tumor suppressor hepatocyte nuclear factor 4 
alpha (HNF4 alpha), which is downregulated during renal cell carcinoma, upregulates 
ankyrin-G (Grigo et al., 2008). In an unrelated study to characterize the gene expression 
during premature aging disease Hutchinson-Gilford progeria syndrome (HGPS), ankyrin-
G was identified as an overexpressed (>100 fold) gene which correlated with increased 
apoptosis in patient fibroblasts (Wang et al., 2006). All these studies indicate that ankyrin-
G as either anti-tumorogenic and/or pro-apoptotic genes (fig.6). The discrepancy between 
pro-tumorogenic and anti-tumorogenic/pro-apoptotic ankyrin-G function may be result of 
the cell context, post-translational modification, function of variable splice variants and 
multiple interaction complexes with different outcomes. For example, an isoform of 
ankyrin-G that lacks the membrane binding domain (ANK-105) and localizes to 
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endosomes/lysosomes, interacts with p85 and plays a role in lysosome mediated PDGF 
receptor downregulation (Ignatiuk et al., 2006).  
   
  
 
      
 
 
 
 
 
 
 
 
 
 
Fig.6. Ankyrin regulates various functions in epithelial cells. Ankyrin-G targets 
various adhesion and ion transporters, required for maintaining epithelial function to 
membrane. Interaction with CD44 and Tiam1 in tumors cells activate protumorigenic 
signaling. Ankyrin-G is upregulated in prematured aging disease Hutchinson-Gilford 
progeria syndrome and overexpression of tumor suppressor HNF alpha whereas 
downregulated by overexpression of tumorigenic Bmi1 and TGF beta.        
 
 
NRAGE 
NRAGE (Neurotrophin Receptor-interacting mAGE protein), also known as MAGE-
D1 and Dlxin1 (Dlx5 interacting protein), is a member of the MAGE (Melanoma Antigen-
encoding GEne) family protein, named for its interaction with neurotrophin receptor (p75). 
The MAGE family members are characterized by the presence of melanoma homology 
domain (MHD). The first reported MAGE family protein was identified as the peptides 
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derived from proteins found in complex with melanoma patients major histocompatability 
complex 1 (MHC1), which could be identified by cytotoxic T lymphocytes in vitro (Pold et 
al., 1999).   
The melanoma antigen (MAGE) family is comprised of two subfamilies, type I, 
which are expressed only in embryonic tissue and melanomas, and type II, expressed 
almost ubiquitously in adult tissues.  The type I members are highly expressed in 
melanomas and are a popular focus of immunotherapy researches as potential tumor 
antigens for developing cancer vaccines. There are more than 50 members identified and 
share a highly conserved ~190 amino acid MAGE homology domain (Barker and Salehi, 
2002; Chomez et al., 2001). NRAGE belongs to type II MAGE family protein which 
expresses in a variety of epithelial, neuronal and tumor tissues (Bertrand et al., 2004; 
Pold et al., 1999) and encodes by locus Xp11.21-p11.23 on chromosome X (Zhang et al., 
2001).   
NRAGE domain structure: NRAGE, identified for the presence of MHD, also 
contains few other domains such as N-terminal domain, DNA polymerase homology 
domain (DNAPIII), WQXP repeat domain, and the C-terminal domain (fig.7). The function 
of N-terminal domain and DNAPIII domain are not characterized. The WQXP repeat 
domain contains 25 repeats of hexapeptide WQXXPXX, conserved in all species of 
MAGE-D1, but there is no homology otherwise in the existing database. The WQXP 
repeat domain interacts with a homeodomain box containing transcription factors 
Dlx5/Msx2 (Masuda et al., 2001). The NRAGE’s MAGE homology domain interacts with 
various membrane and cytoplasmic proteins such as p75-NTR, Unc5H1, Ror2, Necdin, 
and Praja1 (Sasaki et al., 2005). The C-terminal domain of NRAGE interacts with Che-1, 
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an apoptosis antagonizing transcription factor (AATF) (Passananti and Fanciulli, 2007). In 
summary, NRAGE interacts with three groups of proteins such as membrane receptors 
(p75-NTR, unc5H1, and Ror2), transcription factors (Dlx5/msx2 and Che-1), and 
cytoplasmic proteins (XIAP and Praja1).       
 
 
 
          
 
 
 
 
 
Fig.7. NRAGE domain structure and interacting partners. NRAGE contain major 
domains such as DNA polymerase homology domain (DNAPIII), WQXP repeat 
domain (contain 25 repeats of hexapeptide WQXXPXX, and MAGE homology domain 
(MHD). Various membrane, cytoplasmic, and nuclear proteins are identified as 
NRAGE binding protein.    
 
NRAGE interacting partners: NRAGE interacts with membrane, cytoplasmic and 
nuclear proteins (fig.7). The role of NRAGE in context of individual interactions is briefly 
summarized. 
NRAGE was first identified as a p75-NTR interacting protein. The interaction 
increased upon NGF treatment, blocked the physical interaction between p75-NTR and 
trkA and enhanced apoptosis and cell cycle arrest in sympathetic neurons (Salehi et al., 
2000). NRAGE was also identified as axon guidance netrin receptor, unc5H1 interacting 
protein. The interaction enhanced apoptosis in undifferentiated PC12 cells. The 
differentiated PC12 cells downregulated NRAGE and failed to respond to unc5H1 
overexpression. The co-expression of NRAGE and unc5H1 restored the apoptosis 
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sensitivity in differentiated PC12 cells (Williams et al., 2003). The NRAGE-mediated 
apoptosis was result of the recruitment of ubiquitin ligases to IAPs, causing their 
degradation, and by activating Jun-N-terminal Kinases (JNKs) to activate the 
mitochondrial dependent caspase pathway (Salehi et al., 2002). Consistent with this pro-
apoptotic function, NRAGE knockout mice show a developmental defect in neuronal 
apoptosis in the brain (Bertrand et al., 2008).  
NRAGE was identified as homeodomain protein Dlx5 interacting protein (so 
named Dlxin1) and the interaction in turn regulated the Dlx-5 dependent transcription 
activity (Masuda et al., 2001). NRAGE interaction with another MAGE family protein, 
Necdin, was shown to release the Msx1/2 (muscle segment homeobox 1/2) mediated 
transcriptional repression (Kuwajima et al., 2004). The NRAGE function is also regulated 
by its interaction with E3 ubiquitin ligase Praja1. NRAGE is hypothesized to link E3 
ubiquitin ligases to its interacting partners such as Msx2/Dlx5 and affecting their 
stability/transcriptional function (Sasaki et al., 2002). The NRAGE interaction with 
transcription factors has been characterized but their role in transcription regulation is still 
an open ongoing area of discussion.    
Role of NRAGE in cancer: NRAGE is a type II MAGE family protein, expresses 
ubiquitously in all tissue types and interacts with various membrane and nuclear proteins. 
There are various studies performed to understand its role in cancer. The study 
performed in melanoma and pancreatic cancer demonstrated that the adenovirus 
mediated overexpression of NRAGE suppressed cellular motility and cancer motility 
possibility through regulating matrix metalloproteases-2 (MMP-2) activity (Chu et al., 
2007). Similar observations were also made during the study in NRAGE overexpressing 
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breast cancer cells, attributing the effect on p53, p21, and E-cadherin upregulation and 
beta catenin downregulation. Though the effect was only observed on one cell line, 
questioning the universality of this observation (Du et al., 2009). These observations have 
shown the pro-tumorogenic role of NRAGE in tumorogenicity.  
 
 
 
 
 
 
 
 
 
 
 
Fig.8. NRAGE shows pro-apoptotic and pro-tumorigenic function. NRAGE has 
been characterized as pro-apoptotic with reference to p75 and Unc5H1 interaction 
whereas pro-tumorigenic with reference to NF-kB activation and cell depolarization 
activities. The NRAGE role in transcriptional regulation is not well characterized. 
 
Nevertheless, there are other evidences suggesting the pro-tumorigenic role of 
NRAGE. The overexpression of NRAGE disrupts colocalization of E-cadherin/beta 
catenin and translocation of beta catenin to cytoplasm and nucleus in osteosarcoma cells 
U2OS. The loss of cell polarity/adherence junction and localization of beta catenin have 
been implicated in the pro-tumorigenic activity (Onder et al., 2008). Recently, NRAGE 
have been shown to activate NF-kB pathway in non-canonical bone morphogenic protein 
signaling pathway (Matluk et al.). NF-kB activation is well characterized for pro-
inflammatory and pro-tumorigenic pathways. Few other reports have indicated NRAGE 
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over-expression in various cancer patients including lung, kidney and head/neck 
(Bhattacharjee et al., 2001; Boer et al., 2001; Ginos et al., 2004). The effect on cell 
polarity, NF-kB activation and overexpression in various cancer types could account for 
NRAGE’s pro-tumorigenic activity (fig.8).   
There are no mechanistic details for role of NRAGE role in tumor 
progression/cancer. The other proteins related to NRAGE can give some insight about its 
possible role in cancer. One of the related proteins MAGE-A3 supports melanoma cell 
survival, and overexpression in lung cancer correlates with the poor prognosis (Groeper 
et al., 2007; Yang et al., 2007).  The NRAGE orthologue trophinin/MAGE-D3 is over-
expressed in colorectal carcinoma, promoting tumor metastasis (Harada et al., 2007). 
The function of NRAGE is pro-apoptotic with respect to receptors such as p75-NTR and 
Unc5H1 but the possible tumorigenic role in anoikis is not yet tested. The phospho-
tyrosine enriched NRAGE has been identified in immunoaffinity profiling of 
phosphorylated tyrosine in cancer cell lines, suggesting its possible post-translational 
regulation during tumor progression (Rush et al., 2005).  
TBX2 
 
TBX2 belongs to T-Box (TBX) family of transcription factors, known to regulate 
various cellular processes such as embryonic development, cell cycle progression, 
senescence and apoptosis (Abrahams et al.). Various reports have indicated the TBX2 
overexpression in variety of cancer types including melanoma, small cell lung carcinoma, 
breast, pancreatic, liver, and bladder cancers. Recently, TBX2 has been reported to 
promote anchorage independent growth in p53 negative SW13 adenocarcinoma cell line 
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and mouse embryo fibroblast lacking retinoblastoma (pRb) and related pocket proteins 
(p107 and p130) (Ismail and Bateman, 2009; Vormer et al., 2008).  
TBX2 has traditionally been characterized as a transcription repressor. The murine 
TBX2 study suggested its possible function in transcription activation. The transcription 
activation domain was identified as part of the N-terminal domain (Paxton et al., 2002). 
There are various targets of TBX2 including tumor suppressor p14-ARF, p21, and 
NDRG1 (N-myc downregulated gene 1) (Jacobs et al., 2000; Prince et al., 2004; 
Redmond et al.). In contrast, TBX2 has been shown to upregulate hyaluronan synthase 2 
(HAS2) and TGF beta2 as a result of the Bmp-Smad pathway (Shirai et al., 2009). The 
universality of these transcription regulations are yet to be tested.  Few of the TBX2 
targets such as P14-ARF and NDRG1 are briefly described here. 
P19-ARF (P14-ARF in human) was identified as TBX2 target in a screen 
bypassing senescence. TBX2 was shown to attenuate E2F1, Myc or RAS-mediated 
induction of P19-ARF (Cdkn2a). P14-ARF (alternate reading frame) is encoded by INK4 
locus, which also encodes p15 and p16. P14-ARF shares exon2 and exon3 with p16 
gene but the reading frame is completely different. P14-ARF is one of the most frequently 
mutated genes in human carcinoma (Kamb et al., 1994). P14-ARF is involved in various 
signaling pathways such as p53, c-myc and CtBP and promotes apoptosis. The recently 
identified TBX2 target is NDRG1. TBX2 represses NDRG1 in an EGR-1 dependent 
mechanism, to promote proliferation in breast cancer cells (Redmond et al.). NDGR1 is 
previously reported for its function as metastasis suppressor, negatively correlated with 
tumor metastasis (Kovacevic and Richardson, 2006). Its role in anoikis and anchorage 
independence growth is yet to be characterized.  
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SUMMARY   
Anoikis is an important epithelial feature to maintain the cell homeostasis and 
suppress tumor metastasis. The process is supported by various cellular proteins such as 
transcription factors, extracellular proteins, adhesion molecules, cytoskeletal proteins, 
death receptors pathway proteins, Bcl2 family members (pro- and anti-apoptotic proteins) 
and various signaling pathways proteins. During EMT and tumor metastasis, cells 
develop various mechanisms that could change cell behavior and growth pattern. In this 
study, we are studying the role of a cytoskeletal protein ankyrin-G, MAGE family protein 
NRAGE, and a known embryonic and oncogenic transcription repressor TBX2 for their 
role in anoikis and anchorage independent growth. This is a very novel study implicating 
new partners for their role in anoikis and their possible regulations during EMT and tumor 
progression.         
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CHAPTER 2 
MATERIALS AND METHODS 
Cell Culture: The Madrin Darby canine kidney (MDCK), MDA-MB-231, 293T and 
HT1080 cells were maintained in DME medium supplemented with 10% fetal bovine 
serum and 1X penicillin/streptomycin/glutamine. The non-small cell lung carcinoma cell 
line H1299 (NCI-H1299) cells, breast cancer cells Au565 and BT474 were maintained in 
RPMI medium supplemented with 10% fetal bovine serum and 1X 
penicillin/streptomycin/glutamine. MCF-7 cells were maintained in DME medium 
supplemented with 10% fetal bovine serum, 1X penicillin/streptomycin/glutamine and 10 
μg/ml insulin. MCF10a cells, kindly provided by R. Pauley (Karmanos Cancer Center, 
Detroit, MI), were maintained in DME/F12 medium supplemented with 5% horse serum, 
1X penicillin/streptomycin/glutamine, 10 μg/ml insulin, 10 ng/ml EGF, 0.5 μg/ml 
hydrocortisone and 0.1 μg/ml cholera toxin. HMLE, HMLE+shEcad and HMLE+Twist 
cells, kindly provided by the R. Weinberg lab (Whitehead Institute, Cambridge, MA) were 
maintained in the same medium but without cholera toxin (plus 20nM 4-hydroxytamoxifen 
for the Twist cells). I-HUVEC cells (Freedman and Folkman, 2004), kindly provided by the 
Folkman lab (Harvard Medical School, Boston, MA) were maintained in EGM-2 medium 
(Cambrex) plus 5% fetal bovine serum. Derivatives of MCF10a and HMLE cells were 
made by infection with recombinant retroviruses that were packaged by co-transfection 
into the cell line gp2+293 with the vector pAmpho (Clontech). The human NRAGE 
construct from Origene, containing MAGE-D1 transcript variant 2 (778 amino acids, 
accession number NM_006986), was used as a template for all NRAGE constructs. 
NRAGE was PCR-amplified with a forward primer that included a HA-tag sequence and 
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XhoI site, and subcloned into the XhoI-NotI site of MSCV-IRES-puro. To construct 
NRAGE-NLS, the complete NRAGE coding sequence upstream of the stop codon was 
amplified with the same forward primer as above, and with a reverse primer containing an 
NheI site. Separately, the triple NLS sequence from the vector pEYFP-NLS (Promega, 
Madison, WI) was PCR-amplified to produce an NheI-NotI fragment. The NRAGE and 
NLS fragments were three-way ligated into the MSCV-IRES-puro vector. We observed 
that infection of constructs in this vector produced cell lines of variable anoikis-sensitivity 
following puromycin selection, even with the empty vector (data not shown). Therefore, 
the NRAGE and NRAGE-NLS sequences from these constructs were subcloned into the 
XhoI site of pMIG (Addgene, Cambridge, MA) by PCR. Following infection, cells were 
flow-sorted for GFP-positive cells, due to the GFP marker present in the retrovirus. 
Expression of NRAGE was found to be ~three-fold above the endogenous level by 
western blotting with NRAGE mAb clone 48 (BD Biosciences, Pharmigen), and uniform 
expression of NRAGE was verified by immunofluorescence using HA antibody HA.11 
(Covance, Emeryville, CA). P19ARF-knockout and control wild-type mouse embryo 
fibroblasts (MEFs) were kindly provided by Ned Sharpless (University of North Carolina). 
These were immortalized with SV40 T-antigen using the retroviral producer cell line, Zip-
Ter, and T-antigen expression was verified by western blotting. 
Expression constructs: Ankyrin-FL construct was subcloned from pcDNA3-Flag-
rat-ankG190 (a kind gift from Devarajan Prasad) to pcDNA3.1 (-) His-myc. The ank-
delZU5 and ank-delDD were designed by ligating n-terminal and c-terminal PCR products 
in pcDNA3.1 (-) myc-His (Invitrogen, Carlsbad, CA, USA). Ankyrin-MBD, ankyrin-DD and 
ankyrin-ZU5 were made by amplifying individual domains using pcDNA-ankG190 as 
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template and sub-cloning to pcDNA3.1 (-) myc-His. GST-ankDD and GST-ankZU5 were 
subcloned from GFP-ankG270 (rat) (a kind gift from Van Bennett) into pEGB vector. 
GST-unc5H1ZU5, GST-PIDDZU5 and GST-ZO1ZU5 were subcloned from myc-unc5H1 
(a kind gift from Lindsay Hinck), Flag-PIDD (a kind gift from Jurg Tschopp) and ZO1 
construct (a kind gift from W. Hunziker) respectively. The pcDNA3.1-HA-NRAGE (mouse) 
was a kind gift from Lindsay Hinck. The retroviral constructs were engineered either in 
pMSCV-IRES-Puro or pMSCV-IRES-GFP. The HA epitope tag was introduced at n-
terminal and NES/NLS at c-terminal of human NRAGE cDNA.  
Anoikis assays: For caspase activity assays performed on confluent cells, 150,000 
cells were plated per 35mm well, and, after overnight attachment, transfected with 0.3ml 
of a 1.0ml mixture containing 15 µL of 20 µM siRNA and 15 µL of lipofectamine RNAi-
max in a total of 2.3ml Opti-MEM medium (Invitrogen, Carlsbad, CA). Cells were refed 
with their normal growth medium 4-6 hours later and grown for 45 hours post-transfection, 
trypsinized, and resuspended in 1.5ml of medium per time point.  Each time point was 
plated in one 35mm Ultra-low attachment well (Corning), cells were collected by 
centrifuging for 15 seconds at 8,000 rpm in a microfuge tube, washed in ice-cold PBS and 
lysed in 0.2% Triton-X100/PBS+1mM DTT. After clearing lysates at 13,200 rpm for 10 
minutes, samples were assayed for caspase activity in 100 µL of caspase assay buffer 
(20 mM Pipes/100 mM NaCl/1 mM EDTA/0.1 % Chaps/10 % sucrose, pH 7.2/10mM 
DTT) containing 0.15 mM Ac-DEVD-AFC substrate and read in a Molecular Devices 
Gemini XPS fluorimeter.   
For subconfluent cells assayed by DNA fragmentation ELISA: 5x104 cells 
(MCF10a/HMLE) were plated in wells of 6-well dishes. Two duplicate wells with target 
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siRNA and two duplicate wells with control siRNA, using 500 uL of Opti-MEM containing 5 
µL of 20 µM siRNA and 5 µL of lipofectamine RNAi-max, added to a well containing 2.0ml 
of Opti-MEM. SiRNAs for NRAGE and TBX2 were “SmartPools” (Dharmacon).  
After 4-6 hours, cells were re-fed with regular growth medium, and, 24 hours later, 
each well was split into one 60mm dish.  These were further incubated overnight, 
trypsinized, and resuspended in 1.5ml of growth medium per time point that was plated in 
a 35mm Ultralow Attachment well. At each time point, cells were spun down at 8,000 rpm 
for 15 seconds in a microfuge tube, washed in ice-cold D-PBS and lysed in 200 uL of 
0.2% TritonX100/PBS/10mM EDTA or Roche Cell Death ELISA Lysis/Incubation buffer 
that was supplemented with 0.2% TritonX100.  (Note:  without supplementation, this 
buffer did not lyse aggregated MCF10a cells efficiently).  Lysates were cleared at 13,200 
rpm for 10 minutes and, in the case of the first lysis buffer listed above, assayed for 
protein concentration using a Bio-Rad protein assay.  Normalized amounts of lysate 
(usually in the range of 5-15 uL) were then assayed in a total of 100 uL of Roche Cell 
Death ELISA lysis/Incubation buffer in the Roche system and read in a Molecular Devices 
plate-reading spectrophotometer.  TBX2 knockdown was verified on a western blot using 
Santa Cruz pAb (clone H137) and NRAGE knockdown was verified using BD Biosciences 
clone 48 mAb. 
Apoptosis in transiently transfected cells: The effect of ankyrin over-expression on 
apoptosis was measured by over-expressing individual constructs in H1299, 293T and 
cos7 cells and processing the cell lysates for DNA fragmentation ELISA. Briefly, 0.5-1 X 
105 cells were plated in 6-well plates. Next day, the cells were transfected using 
lipofectamine LTX (H1299) (Invitrogen, Carlsbad, CA, USA) or fugene 6 (293T or Cos7) 
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(Roche, Indianapolis, IN, USA) with expression constructs (with or without siRNA) using 
the manufacturer recommendations. The cells were lysed after 40-48 hours of 
transfection and lysates were assayed for DNA fragmentation ELISA. The expression of 
each construct was confirmed by immunoblot analysis. 
Cell fractionation: The MDCK cells were grown in cell culture inserts (Fisher 
Scientific, Pittsburgh, PA, USA) and allowed to grow till confluence. Once the cells were 
of required confluence, they were used either attached or detached (trypsinized). The 
cells were washed with 1XHBSS (Hanks Balanced Salt Solution, Invitrogen, Carlsband, 
CA, USA), solution followed by washing with ice cold hypotonic buffer (5mM Tris, pH 7.5, 
1mM EGTA, 5mM MgCl2 and 1mM DTT with complete protease inhibitor) for 3 minutes. 
The cells were washed again with 1XHBSS followed by 200ul CSK (cytoskeletal) buffer 
(pH 6.8 PIPES 10mM, 300mM sucrose, 3mM MgCl2, NaCl 50mM and 0.5% Triton X100 
with complete protease inhibitor) treatment for 3 minutes. Supernatant was collected and 
dissolved into equal amount of 2XSDS loading buffer and pellet was dissolved in 400ul of 
1XSDS loading buffer followed by boiling for 5 minutes. The equal volume was used for 
immunoblot analysis.         
Immunofluorescence: For ankyrin (Anti-rabbit 1:200) / e-cadherin (Anti-mouse 
1:50) localization in sub-confluent and confluent cells, methanol fixed MDCK cells were 
used. Briefly cells were plated and grown for the required density, fixed and processed for 
immuno-fluorescence (IF) using above mentioned primary and compatible secondary 
antibodies (anti-mouse Alexa 488 and anti-rabbit Alexa 594, Invitrogen, Carlsband, CA, 
USA) and images were taken on Zeiss fluorescence microscope. The effect of ankyrin-
FL/DelUPA on NRAGE localization experiment was performed in HT1080 cells. Briefly, 
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cells were co-transfected with HA-NRAGE and ankyrin/control constructs followed by 4% 
PFA fixation after 36-40 hours. The fixed cells were processed for IF using anti-HA 
(mouse, 1:500) and anti-ankyrin antibodies.  
The effect of ankyrin depletion on NRAGE localization was performed in MCF10a 
cells. Briefly, 30-40% confluent cells were transfected using lipofectamine RNAimax 
(Invitrogen, Carlsband, CA, USA) as mentioned earlier. The cells were treated with 6nM 
leptomycin B for 30 minutes followed by 4% PFA fixation (15 minutes), PBS washing (3 
times),  permeabilization with 0.2% triton X-100 for 5 minutes, washing with 100mM 
Glycine containing PBS-tween20 (0.1%)  for 3 X 5 minutes, primary antibody incubation 
for 1 hour, PBS-tween20 washing for 3 X 5 minutes, secondary antibody treatment for 30 
minutes, PBS-tween20 washing for 3 X 5 minutes followed by fixing cells with DAPI.   
The localization of NRAGE in HMLE, HMLE/shECAD and HMLE/ER-Twist cells 
were performed as follows. 1 X 105 cells were plated on cover slips and they were 
allowed to grow for 2-3 days. HMLE/ER-Twist cells were maintained in 4-OH-tamoxifen 
(after 10 days initial treatment). The cells were treated with 6uM leptomycinB followed by 
PFA fixation and IF as mentioned earlier. The nuclear and total NRAGE signals for 
individual images were quantitated using image j software (NIH) and the average signal 
was compared for stastical significance using free online version of graphPad software 
(http://www.graphpad.com) and Microsoft excel software. 
For the HT1080 co-transfection experiment, HA-mouse-NRAGE (Sasaki et al., 
2002) in pcDNA3.1 was cotransfected (Fugene-HD) with 3XFLAG-ankyrin-G (210 kDa 
isoform) constructs generated in the vector p3XFLAG-CMV-10 (Sigma). Twenty-four 
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hours later, coverslips were fixed and doubly stained with rat anti-HA mAb (Covance) and 
mouse anti-FLAG M2 (Sigma) using procedures outlined above. 
Protein interaction methods: For co-immunoprecipitation of NRAGE with TBX2, 
MCF10a and HMLE cells (two confluent 100mm dishes) were washed and lysed in 
standard IP buffer (25mM Tris pH8, 200mM NaCl, 10% glycerol, 0.5% Triton-X100, 1X 
complete protease inhibitor cocktail, Pierce).  Lysates were pre-cleared at 13,200 rpm for 
10 minutes and then pre-absorbed for 30 minutes with 65 µL of 50% protein A-sepharose 
(GE Healthcare) that had been pre-equilibrated in standard IP buffer with 10mg/ml BSA 
+10 mg/ml ovalbumin.  After clearing, 3 µg of NRAGE pAb (Santa Cruz sc-28243) or 
normal IgG (Covance) was added and samples were incubated 2 hours at 4 degrees with 
rotation.  Protein A-sepharose (40 uL) was then added and incubation was continued for 
an additional hour.  After three washes with standard IP buffer, samples were boiled in 2X 
SDS sample buffer (containing 10% β-mercaptoethanol), loaded onto a pre-cast 4-20% 
polyacrylamide gel (Invitrogen, Carlsbad, CA) and analyzed on a western blot for TBX2 
(Santa Cruz pAb sc-48780) or NRAGE (BD Biosciences mAb, clone 48); Clean-blot 
secondary antibody (Pierce) and anti-mouse-HRP (BioRad) were used respectively for 
the detection of these antibodies, followed by development with West Pico ECL reagent 
(Pierce). 
For detection of ankyrin-NRAGE complexes, the method above was modified as 
follows. Five minutes prior to lysis, cells were washed and incubated on ice with hypotonic 
buffer (5mM Tris pH 7.5/1mM EGTA/5mM MgCl2/1mM DTT/1X complete protease 
inhibitors, Pierce). This was found to result in better ankyrin-G detection, presumably due 
to the influx of protease inhibitors into the cells prior to lysis. Following 
 
 
50 
immunoprecipitation as above, proteins were transferred to PVDF membranes overnight 
at 30V in transfer buffer with the methanol reduced to 5%.  Ankyrin-G was detected using 
a Santa Cruz pAb (sc-28561), a pAb kindly provided by Vann Bennett (Duke University) 
or pAB kindly provided by Deborah Anderson (Saskatchewan Cancer Institute, 
Saskatoon, Canada). For ankyrin-G immunoprecipitation, antibody was developed 
against the C-terminal domain. 
For transient co-transfections, 293T cells were plated in 35mm collagen-coated 
wells and co-transfected, using 150 µL per well of cells (in 2.0 ml of Opti-MEM) of a 
solution containing 200 µL Opti-MEM, 1 µg of each expression construct (2 µg total DNA) 
and 6 µL of Fugene-HD (Roche).  After four hours, cells were returned to normal growth 
medium (DMEM+10% fetal bovine serum+1X penicillin-streptomycin-glutamine).  Twenty-
eight to 36 hours later, cells were collected by pipetting each well in 1.0 ml of cold PBS, 
pelleted in a microfuge at 8,000 rpm for 15 seconds, and lysed in standard IP buffer (600 
µL), followed by preclearing the lysates at 13,200 rpm for 10 minutes.  For GST 
pulldowns or FLAG pulldowns, 40 µL of glutathione-sepharose (GE Healthcare) or FLAG-
agarose (Sigma), pre-equilibrated in standard IP buffer + 10mg/ml BSA +10mg/ml 
ovalbumin, was added, and samples were rotated at 4 degrees for 1.5-2 hours.  Following 
three washes in standard IP buffer, GST pulldowns were eluted with 40 µL of 2X SDS 
sample buffer (containing 10% β-mercaptoethanol),  by boiling.  FLAG pulldowns were 
eluted with 50 µL of 0.1M glycine pH 2.8 at 4 degrees for 10 minutes; after removal of the 
beads by spinning, 40 µL of the supernatant was neutralized by the addition of 8.8 µL of 
0.5M Tris pH7.5.  An equal volume of 2X SDS sample buffer (containing 10% β-
mercaptoethanol) was added and all samples were analyzed on western blots for GST 
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(anti-GST mAb, Santa Cruz), FLAG (anti-FLAG M2, Sigma) or HA (HA.11 mAb Ascites, 
Covance).   
Expression constructs used for the interaction domain mapping experiments were 
as follows: To generate GST-NRAGE fusion expression constructs, NRAGE sequences 
were amplified (Phusion polymerase, NEB) from the Origene clone, subcloned into the 
XhoI-HindIII site of pcDNA3.1mychis-A(-) and then re-subcloned into the SalI-NotI site of 
the mammalian GST fusion expression vector pEBG2. The full-length mouse TBX2-
3XFLAG expression construct was kindly provided by Colin Goding (Oxford University). 
For the experiments mapping the domain of NRAGE that interacts with ankyrin, the GST-
NRAGE fusion constructs were co-transfected with a clone, kindly provided by Deborah 
Anderson (Saskatchewan Cancer Institute, Saskatoon, Canada) that expresses the p105 
isoform of mouse ankyrin-G in the vector p3XHA.  For experiments to map the domain of 
ankyrin-G that interacts with NRAGE, human ankyrin-G fragments from the Imagenes 
(Berlin, Germany) clone DKFZp686P17114, containing accession number BX537917, 
were amplified by PCR as BamHI-HpaI fragments and subcloned into the BglII-HpaI site 
of the p3XHA vector.   
Soft agar assays: SW13 adrenocortical carcinoma cells (ATCC) were maintained 
in DME+10% fetal bovine serum + 1Xpenicillin-streptomycin-glutamine. SW13 cells over-
expressing TBX2 were generated by infection with mouse TBX2-FLAG that had been 
subcloned into the retroviral vector pMIG followed by flow-sorting for GFP positive cells 
and western blotting to confirm expression. Stable NRAGE knockdown derivatives were 
then generated by infection of these TBX2-expressing cells with an NRAGE-shRNA 
retrovirus in the vector pRS (Origene). The MDA-MBA-435 cells were also generated 
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using NRAGE-shRNA retrovirus. 1.0 ml of 0.7% low melting agarose in complete medium 
was mixed with 10,000 SW13-TBX2/pRS or SW13-TBX2/shNRAGE cells and plated onto 
6 wells each of 24-well ultra low attachment plates (Costar). 
The cells were grown for 7-10 days and soft agar media was refed each 4-5 days. 
500 cells of SW13-TBX2/pRS and SW13-TBX2/shNRAGE cells were plated onto three 
wells of tissue culture treated 6-well plates and grown for 7-10 days. Six images from 
each well of soft agar colonies (>8 cells/colony) were photographed using 10X 
magnification lens (Zeiss Axiovert 200M) and averaged. The averaged soft agar colonies 
were normalized against the attached colony numbers.   
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CHAPTER 3 
ROLES OF ANKYRIN AND INTERACTING PROTEINS IN ANOIKIS  
Introduction 
Ankyrin is a family of cortical cytoskeletal proteins, known to link membrane proteins to 
the actin cytoskeleton. The epithelial isoform of ankyrin, ankyrin-G required in membrane 
biogenesis, targeting of various membrane proteins including the adherens junction 
protein E-cadherin and Na+-K+-ATPase, etc. (Kizhatil and Bennett, 2004; Kizhatil et al., 
2007). Ankyrin-G is known to have pro-apoptotic domains such as ZU5 and death 
domain, implicated in regulation of apoptosis (Feinstein et al., 1995; Williams et al., 2003). 
The sub-membrane localization and presence of pro-apoptotic domains (ZU5 and death 
domains) indicated that ankyrin-G might be important for regulation during cell-
extracellular matrix dissociation induced apoptosis (anoikis) (Frisch and Francis, 1994).   
The role of ankyrin-G in apoptosis hasn’t been characterized well. The evidence from 
renal ischemia reperfusion studies provided some experimental evidence. The MDCK 
cells depleted for ATP abolished ankyrin-spectrin association, mislocalization of ankyrin-
Na+-K+-ATPase, and the loss of Na+-K+-ATPase function affecting ion homeostasis 
(Woroniecki et al., 2003). In cells undergoing ischemia reperfusion, ankyrin-G associated 
strongly with Fas and FADD and induced the apoptotic response (Del Rio et al., 2004). 
Ankyrin-G has been found to overexpress in the fibroblast of HGPS (Hutchinson-Gilford 
Progeria Syndrome) patients, a pre-mature aging disease and correlated with increased 
apoptosis (Wang et al., 2006). Ankyrin-G has also been shown to downregulate in 
multiple types of cancer (Glinsky et al., 2005). Few reports have indicated the role of 
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ankyrin-G in promoting metastasis by interaction with CD44 and Tiam1 (Bourguignon, 
2001). Our study reveals the biological role of ankyrin-G through its interaction partners.   
Results 
Ankyrin-G colocalizes with E-cadherin: It is established that the epithelial adherens 
junction protein E-cadherin is a molecular partner of ankyrin-G (Kizhatil et al., 2007; 
Nelson et al., 1990). Ankyrin-G, which is required for lateral membrane biogenesis, helps 
E-cadherin to localize in lateral membranes (Kizhatil and Bennett, 2004; Kizhatil et al., 
2007). The co-immunofluorescence microscopy experiment in MDCK (Madrin-Darby 
canine kidney) cells demonstrated the co-localization of E-cadherin and ankyrin-G in 
interacting (confluent) and non-interacting (subconfluent) cells (fig.1a). These two proteins 
exhibit diffused cytoplasmic localization in non-interacting cells, whereas they shifted to 
membrane junctions in interacting cells. The MDCK cells were also used for subcellular 
fractionation experiments and despite the cellular localization, ankyrin-G remained 
associated with the cytoskeletal fraction (fig.2b).  Additionally, a recent publication 
reported that the loss of E-cadherin leads to anoikis resistance and increased metastasis 
(Onder et al., 2008). We used human mammary epithelial (HMLE) cells and the cells 
which have undergone epithelial-mesenchymal-transition such as HMLE-shECAD (stable 
knockdown of E-cadherin) and HMLE/ER-Twist (4-OH tamoxifen inducible Twist) cells. 
The expression of ankyrin-G correlated with E-cadherin and downregulated during EMT 
(fig.1c). These data suggest that E-cadherin is required for the expression/stability of 
ankyrin-G in an epithelial cell. 
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Loss of cell-matrix association affects ankyrin-G sub-cellular localization 
 
 
 
 
 
 
 
 
 
Fig.1. Ankyrin-G is a functional E-cadherin partner. (a.) The non-interacting (sub-
confluent) and interacting (confluent) MDCK (Madrin-Darby canine kidney) cells were 
processed for ankyrin-G and E-cadherin co-immunofluorescence. (b.) The sub-confluent 
(SC) and confluent (C) MDCK cells were processed for cytoskeletal fractionations and 
triton soluble (S) and insoluble (I) fractions were probed for ankyrin-G, E-cadherin and 
beta actin. (c.) The mammary epithelial cells HMLE and the cells undergone EMT, 
HMLE-shECAD (cell line expressing stable E-cadherin shRNA) and HMLE/ER-TWIST, 
lysates were probed for ankyrin-G (Deborah Anderson) and beta actin antibodies. The 
HMLE-shECAD and HMLE/Twist have a low level of E-cadherin expression. 
 
The effect of cell-extracellular matrix dissociation was tested on ankyrin-G in 
MDCK cells (fig.2). In contrast to cytoskeletal localization in interacting cells, ankyrin-G 
relocalized to the cytoplasmic pool in the early detached fractionated cell lysates. In these 
lysates, GAPDH remained cytosolic whereas beta actin pre-dominantly remained 
cytoskeletal. Spectrin beta2, the cytoskeletal partner of ankyrin-G also re-localized 
significantly to cytoplasm. We hypothesized that the re-localization of ankyrin-G from 
cytoskeleton to cytoplasm must be critical for regulation of anoikis in epithelial cells.    
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Fig.2. Ankyrin-G 
localization is affected 
by cell-matrix 
dissociation. Attached 
confluent (0 min.) and 
cell-matrix dissociated 
cells (5 min. and 10 
min.) were subjected to 
cytoskeletal fractionation 
assay. The soluble (S) 
and insoluble (I) lysates 
were probed for ankyrin, 
GAPDH, beta actin and 
spectrin.   
 
Effect of suspension on ankyrinG-spectrinβII interaction: Loss of cell-extracellular 
matrix interaction resulted in localization of ankyrin-G from cytoskeleton to cytoplasm. We 
further tested the effect on cell-extracellular dissociation on ankyrin-G and spectrin-beta2 
interaction in MCF10a cells. The lysates from attached and suspended cells were 
immunoprecipitated with ankyrin-G and blotted either with ankyrin-G or spectrin-beta2. 
The data suggested that the interaction between ankyrin-G and spectrin-beta2 was lost 
during early suspension (30 minutes suspension). The enrichment of predominantly 
cytoplasmic ankyrin-G may result in loss of ankyrin-spectrin interaction. We also tested 
the effect of suspension on ankyrin-G protein level. The cells were suspended upto 24 
hours and lysates were subjected to ankyrin-G immunoblot. The data suggested that 
ankyrin-G protein level increased during suspension. It is not clear if the increase was due 
to transcription/translation or result of protein stability. Loss of cell-extracellular matrix 
interaction promotes apoptosis (anoikis), and an increase in ankyrin-G level correlates as 
a positive regulator of anoikis. 
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 Fig.3. Loss of cell-extracellular matrix 
interaction promotes dissociation of 
ankyrinG and spectrin-beta2 
interaction and upregulation of 
ankyrin-G. (a). Cell lysates from attached 
(At.) and suspended MCF10a cells (0, 10 
and 30 minutes respectively) were 
immunoprecipitated either with rabbit 
control (c) or rabbit ankyrin-G antibodies. 
Enriched lysates were immunoblotted 
with ankyrin-G and spectrin-beta2 
antibodies (b). MCF10a cells were 
suspended to 24 hours and lysates were 
subjected to ankyrin-G and RIP1 (control) 
immunoblots.   
 
Overexpression of ankyrinG induced apoptosis through ZU5 and death domain: 
The cell-extracellular matrix dissociation results in re-localization of ankyrin-G from 
cytoskeleton to cytoplasm (fig.2). The relocalization resulted in ankyrinG-spectrin beta2 
dissociation and an increased ankyrin-G level (fig.3). The cytoplasmic ankyrin-G and its 
upregulation could be critical in anoikis initiation. To test the effect of ankyrin-G 
overexpression, we used the transient overexpression strategy in various mammalian cell 
lines. The overexpression of ankyrin resulted in induction of apoptosis in several cell lines 
such as 293T, cos7, and H1299. Interestingly, the overexpression of ankyrin-G correlated 
with increased apoptosis in fibroblasts in HGPS patients (Wang et al., 2006). We further 
tested the effect of individual domains by either using deletion constructs (delZU5 or 
delDD or delZU5-DD) or domain specific constructs (ZU5 or DD or MBD). Based on the 
apoptosis data (DNA fragmentation assay), overexpression of ankyrin-G induced 
apoptosis was dependent on ZU5 and death domain and the construct lacking ZU5/death 
domain with only ankyrin repeats (MBD) failed to induce apoptosis (fig.4). In principle, this 
apoptosis could occur through multiple mechanisms, either through the individual ZU5 
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domain or the individual death domain.  Consistent with this duality of mechanisms, the 
deletion of the ZU5 domain or the death domain alone had only a minor effect on 
apoptosis. The ankyrin repeat/membrane binding domain (MBD), which mediates ankyrin 
interactions with membrane proteins, did not induce apoptosis, indicating that the deletion 
of both the ZU-5 and death domains abrogated apoptosis. This result also indicated that 
the severance of actin cytoskeleton-membrane association was insufficient for apoptosis 
induction. The ZU5 domian only and delZU5 constructs induced apoptosis equally well 
whereas ankyrin death domain (ankDD) only and deletion domain (delDD) construct of 
ankyrin significantly induced apoptosis, suggesting that the apoptotic mechanisms are 
different. The death domain is the major domain in apoptosis induction whereas ZU5 
domain mediated apoptosis might be result of interference with spectrin-ankyrinG 
interaction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4.The ZU5 and death domain of ankyrin-G are pro-apoptotic. NCI-H1299 cells 
were transfected with the indicated ankyrin-G and empty vector (V) constructs. At 45 
hours post transfection, cell lysates were assayed for DNA fragmentation. The 
expression of various constructs was confirmed by tetra-His antibody immunoblot.
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Transient knockdown of ankyrin-G enhances anoikis: Epithelial-mesenchymal-
transition (EMT) results in downregulation of ankyrin-G (fig. 1c).  EMT correlates with 
anoikis resistance. Transient overexpression of ankyrinG induced apoptosis in various 
epithelial and cancer cells (fig. 3). Based on the preliminary data, we hypothesized that 
ankyrin-G to be an anoikis promoter. We tested the effect of ankyrin-G knockdown on 
anoikis in mammary epithelial cells (MCF10a). Contrary to our hypothesis, knockdown of 
ankyrin-G increased the anoikis response, suggesting its role as a possible pro-survival 
protein.  
 
 
Fig.5.Transient 
knockdown of ankyrin-
G enhances anoikis.  
MCF10a cells were 
transfected with luciferase 
or ankyrin-G siRNA and 
at 45-48 hours post-
transfection, cells were 
suspended for the 
indicated time and lysates 
were assayed either for 
caspase activity (Vmax) 
or DNA fragmentation. 
The ankyrin-G 
knockdown was 
confirmed by immunoblot. 
Tubulin was used as 
loading control.   
Ankyrin-G interacts with various other membrane and cytoplasmic proteins 
involved in adhesion, cytoskeletal assembly and apoptotic processes. It can affect 
apoptosis/anoikis by multiple protein interactions and cellular functions. Ankyrin is 
downregulated by various tumor promoting agents in many tumor types. The effect of 
ankyrin-G depletion on anoikis is unexpected but it can be explained by various 
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interactions such as CD44 and Na+-K+-ATPase and related pro-survival function. It is 
reported that inhibition of Na+-K+-ATPase by its inhibitor ouabain results in enhanced 
anoikis in cancer cells and prevents distant tumor formation (Simpson et al., 2009). The 
absence of ankyrin-G from the cytoskeleton has been reported to affect Na+-K+-ATPase 
localization and activity (Woroniecki et al., 2003) during ischemia reperfusion and ATP 
depletion. It is also conceivable that certain splice variants and/or post-translational 
modifications of ankyrin-G may have alternate cellular functions.  
Effect of dominant negative form of ankyrin (ANK-105) overexpression on anoikis:  
 
Fig. 6. The ankyrin-G isoform lacking 
membrane binding domain 
suppresses anoikis. The ankyrin-G 
splice variant (ANK-105) which lacks 
membrane binding domain (MBD) was 
stably expressed in MCF10a cells and 
compared for anoikis with vector 
(pMIG) expressing cells.  
Functional ankyrin-G contains the membrane binding domain (MBD), which contains 24 
ankyrin repeats (AR), spectrin binding domain (ZU5-A), ZU5-UPA-DD supermodule and 
the C-terminal domain. There are splice variants of ankyrin-G which do not contain the 
membrane binding domain (MBD) and they have been named according to their sizes i.e. 
ANK-105 and ANK-120, respectively (Ignatiuk et al., 2006). These variants can interact 
with spectrin but can’t interact with membrane proteins such as E-cadherin, CD44, and 
Na+-K+-ATPase. We tested the effect of overexpression of the dominant negative form of 
ankyrin-G on anoikis in MCF10a cells. Over-expression of ANK-105 resulted in anoikis 
suppression in MCF10a cells. Considering that this splice variant doesn’t link membrane 
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proteins to the actin cytoskeleton and acts as a dominant negative, a functional 
cytoskeletal ankyrin-G might act as positive regulator of anoikis.   
Loss of ankyrin-G destabilizes EGFR: Transient knockdown of ankyrin-G 
enhanced anoikis. This was contrary to the observation that ankyrin-G is downregulated 
during EMT. Anoikis and EMT data in turn suggest that ankyrin-G may have a pro-
apoptotic as well as pro-survival function depending upon the localization, interaction 
partners and cellular contexts. We hypothesized that ankyrin-G might be supporting pro-
survival function of membrane proteins and so its loss would enhance anoikis. To 
understand this phenomenon, we knocked down ankyrin-G and looked at signaling 
proteins in attached and cell-extracellular matrix dissociated MCF10a cells. The loss of 
ankyrin-G resulted in destabilization of EGFR at 6 hours of cell suspension (Fig. 7a). In 
another experiment performed in HMLE cells, knockdown of E-cadherin and ankyrin 
resulted into destabilization of full length EGFR (~180 kDa) and increased the ~42 kDa 
cleavage product (Fig. 7b).   Expression of EGFR is associated with cell survival and 
proliferation and is known to be overactive in many carcinoma types. EGFR is shown to 
activate various pro-survival activities such as activating MAP Kinase pathways, 
suppression of pro-apoptotic proteins such as Bim and stabilization of the sodium/glucose 
cotransporter 1 (SGLT1) (Collins et al., 2005; Reginato et al., 2003; Weihua et al., 2008). 
Ankyrin-G mediated stabilization of EGFR is a novel finding, suggesting its possible role 
in EGFR membrane localization and stability. 
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 Fig.7. Ankyrin-G stabilizes EGFR in mammary epithelial cells. (a.) MCF10a cells 
were transiently knocked down with luciferase (luc) or ankyrin (ank) siRNA and 0 and 
6 hours suspension lysates were were subjected to EGFR and ERK immunoblots. 
(b.) HMLE cells were knocked down for luciferase (LUC) or ankyrin/E-cadherin (E+A) 
and membrane fraction was probed for EGFR. The knockdown was confirmed with 
E-cadherin, ankyrin and tubulin immunoblots.    
 
Ankyrin-G interacts with death domain proteins RIP1 and TRADD: Ankyrin-G 
contains a death domain, known for forming homo- and hetero-dimers. To monitor the 
ankyrin death domain interaction partners, we screened other death domain proteins for 
interaction. The interaction screen was performed through cotransfection of GST-ankDD 
and other death domain proteins in 293T cells, and lysates were enriched with glutathione 
sepharose beads. The ankyrin death domain (ankDD) interacting partners were members 
of the TNF signaling pathway (i) RIP1 (Receptor interacting protein with death domain), 
and (ii) TRADD (TNF receptor interacting adaptor containing death domain). RIP1 
interaction was further confirmed in MCF10a, HMLE and MDCK cells. RIP1 has 
previously been demonstrated for anoikis regulation (Kamarajan et al., ; Kurenova et al., 
2004).   
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Fig.8. Ankyrin-G interacts with death domain proteins RIP1 and TRADD. (a.) FLAG-
RIP1 or (b.) His-tagged death domain of TRADD (His-TRADDDD) construct was co-
transfected with GST or GST-ankyrinDD and lysates were enriched with glutathione 
sepharose beads. The pulldown samples were blotted for GST and FLAG (for RIP1) or His 
(TRADD-DD). (c.) The lysates of MCF10a and HMLE cells (upper panel) or attached (0 
min.) and detached (10 min.)  MDCK cells were immunoprecipitated with rabbit control IgG 
(C) or Ank-G (A) and samples were immunoblotted with ankyrin-G and RIP1.   
Ankyrin induced apoptosis is RIP1 dependent: The ankyrin-G interacting proteins RIP1 
and TRADD are well characterized for their roles in TNF mediated anti-apoptotic and pro-
apoptotic pathways. RIP1 functions through a switch mechanism and its cleavage by 
caspase-8 promotes the pro-apoptotic function. We tested the role of RIP1 in ankyrin-G 
induced apoptosis and RIP1 was depleted by transient knockdown. Interestingly, ankyrin-
G induced apoptosis was partially rescued by the RIP1 depletion in NCI-H1299 cells 
(Fig.8).   
   
 
 
 
64 
  
 
 
 
 
 
 
 
Fig.9. RIP1 promotes ankyrin-G dependent apoptosis. H1299 cells were co-
transfected either with vector/ankyrin-G expression constructs and luciferase 
(Luc)/RIP1 siRNA and lysates were processed for DNA Fragmentation assay. 
Expression of ankyrin-G and depletion of RIP1 was confirmed by anti-His and RIP1 
immunoblots. Alpha tubulin immunoblot was performed as loading control. 
 
RIP1 is a known regulator of anoikis (Kurenova et al., 2004). RIP1 counteracts 
FAK pro-survival function by interacting with its N-terminal domain. This observation has 
recently been extended by confirming this interaction and RIP1 shuttling between death 
domain receptor mediated pro-apoptotic pathway and FAK mediated pro-survival 
signaling (Kamarajan et al.).  
Modulation in TRADD expression enhances anoikis: TRADD (TNFR1-associated 
death domain protein) is an adaptor protein known to link TNF receptor with Caspase-8 
and RIP1 and modulate pathway by activating a pro-survival pathway activating NF-kB or 
pro-apoptotic pathway activating caspase-3. Our interaction screen identified TRADD as 
an ank-DD interaction partner. We tested the role of TRADD in anoikis either by retroviral 
mediated stable expression or transient knockdown in mammary epithelial cells MCF10a. 
Surprisingly, either over-expression or transient knockdown of TRADD enhanced anoikis 
compared to control cells. These surprising data suggest a novel function of TRADD in 
anoikis, which may possibly modulate TNF receptor pathway for NF-kB/caspase-3 
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activation, which is yet to be characterized. It will also be interesting to understand how 
this function of TRADD is regulated by ankyrin-G. 
 
 
 
Fig.10. Changes in 
TRADD expression 
enhance anoikis. (a.) 
TRADD was transiently 
knocked down in 
MCF10a cells and post 
45 hour transfection, cells 
were suspended for 
6hours and lysates were 
compared for caspase 
activity. Knockdown was 
confirmed by TRADD and 
beta tubulin immunoblot. 
(b.) pBabe and pBabe-
TRADD expressing 
MCF10a cell lysates were 
compared for caspase 
 
Discussion 
 
Ankyrin-G is required for targeting interacting membrane proteins to the 
cytoskeketon (Ango et al., 2004; Mohler and Bennett, 2005). In our study, we reiterated 
the functional relationship between E-cadherin and ankyrin-G. Apart from co-localization 
in non-interacting and interacting cells, we found that ankyrin-G was downregulated in 
epithelial cells with E-cadherin stable knockdown (HMLE+shECAD), probably by 
activating an unknown transcriptional pathway (Onder et al., 2008). The cell fractionation 
experiments showed the cytoskeletal association of ankyrin-G in non-interacting and 
interacting cells. Surprisingly, ankyrin-G dissociated from the cytoskeleton and moved to 
detergent soluble cytoplasmic fraction in early detached cells, with loss of spectrin 
interaction and increase in ankyrin-G protein level. Incidentally, this observation correlates 
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with events during ATP depletion/renal ischemia reperfusion which also resulted in loss of 
ankyrin-spectrin association in a time dependent manner (Woroniecki et al., 2003). The 
cells lacking extracellular matrix association are known to have metabolic defects (low 
ATP level) (Schafer et al., 2009). The data suggest that change in ankyrin-G localization 
in early detached cells may be involved in initiating anoikis as the cells lacking ankyrin 
(HMLE+shECAD) are resistant to anoikis. The overexpression of ankyrin-G in Cos7 and 
H1299 (express very low endogenous ankyrin-G, unpublished observation) cells, induced 
apoptosis. The apoptosis was dependent on presence of ZU5 and the death domain. 
These data correlate with Fas ligand induced apoptosis in ankyrin-G expressing MDCK 
cells which required death domain (Del Rio et al., 2004). The ZU5 effect on apoptosis 
correlates with a previous report suggesting that the expression of spectrin binding 
domain of ankyrin-R made HeLa cells detach from culture within few hours of 
transfection, probably as a dominant negative function (Kolondra et al., 2008). 
We tested the effect of ankyrin-G knockdown on anoikis in MCF10a cells. 
Surprisingly, the knockdown of ankyrin-G enhanced anoikis sensitivity, suggesting its pro-
survival function. Ankyrin-G pro-survival function can be explained by its interaction with 
Na+-K+-ATPase and CD44 interactions. Cell treatment with Na+-K+-ATPase inhibitor 
ouabain enhances anoikis response in cancer cells (Simpson et al., 2009). Ankyrin-G is 
required for Na+-K+-ATPase localization and function. In absence of ankyrin-G, Na+-K+-
ATPase failed to localize to the lateral membrane and the mislocalized enzyme loses its 
activity (Kizhatil and Bennett, 2004; Woroniecki et al., 2003). Ankyrin-G promotes CD44 
mediated ovarian, breast and prostate carcinoma (Bourguignon, 2001; Bourguignon et 
al., 2008). The knockdown of CD44 enhances anoikis sensitivity in MCF10a cells (Ben 
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Cieply, unpublished data). The ankyrin-G knockdown in CD44 independent cells such as 
HMLE may exhibit a different response. Preliminary data suggest that ankyrin-G 
knockdown doesn’t affect anoikis in HMLE cells which needs to be verified. There are 
possibilities that different splice variants, post-translational modification and proteolytic 
cleavage products affect ankyrin-G function. We have observed that the ankyrin-G 
undergoes proteolytic cleavage in MCF10a cells, whereas cells dissociated from 
extracellular matrix lose it. In tumor tissue lysates, we have observed various large forms 
of ankyrin-G compared to mostly proteolytic cleaved forms of ankyrin-G in normal tissue 
lysates (personal observation). The phospho-tyrosine enriched ankyrin-G was identified in 
the immunoaffinity profiling of phosphorylated tyrosine in cancer cell lines, suggesting its 
possible post-translational regulation during tumor progression (Rush et al., 2005). Our 
data also indicate that ankyrin-G stabilizes EGFR in attached (HMLE) and detached 
(MCF10a) cells.  
In cotransfection experiments, we found RIP1 and TRADD as ankyrin death 
domain interacting partners. Ankyrin-G interaction was confirmed in mammalian cells 
(HMLE and MCF10a cells). RIP1 co-operated with ankyrin-G induced apoptosis. The 
TRADD and ankyrin-G interaction couldn’t be confirmed in co-immunoprecipitation 
experiments. Either overexpression or downregulation of TRADD enhance anoikis 
sensitivity, possibly by affecting the TNF signaling response. The TRADD over-
expressing cells have dramatically low level of ankyrin-G, suggesting possible effect on 
protein stability, due to increased apoptotic events. Ankyrin-G seems to be a very 
complex protein, regulating various cellular processes. 
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CHAPTER 4 
NRAGE, AN ANKYRIN-G INTERACTING PROTEIN SUPPRESSES ANOIKIS 
Introduction 
NRAGE (Neurotrophin Receptor-interacting mAGE protein) is a melanoma antigen 
(MAGE) family protein, identified through interaction with neutrotrophin receptor p75-NTR. 
It is also known as MAGE-D1 and Dlxin1 (Dlx5 interacting protein). It interacts with the 
ZU5 domain containing protein, Unc5H1 (netrin receptor) and induces apoptosis in PC12 
cells (Williams et al., 2003). Consistent with its role in neuronal apoptosis, the NRAGE 
knockout mouse showed defects in developmental apoptosis, quite similar to the p75 
knockout mouse.   
NRAGE also interacts with transcription factors such as Dlx5, Msx1/2, and Che1 to 
modulate their function. Interacting proteins at the cell membrane as well as in the 
nucleus require a tight regulation in nucleocytoplasmic transport. NGF treatment 
accumulated NRAGE at the cell membrane, whereas co-transfection with Msx2 promoted 
nuclear localization (Matsuda et al., 2003; Salehi et al., 2000).  
There are reports that implicate the role of NRAGE in tumorigenesis but the exact 
mechanisms are not reported (Chu et al., 2007; Du et al., 2009). In this study, we have 
identified a novel cytoskeletal (ankyrin-G) and a transcription repressor (TBX2) as 
NRAGE interaction partners. These interactions have been characterized for their roles in 
regulation of nucleocytoplasmic transport, anoikis and anchorage independent growth in 
epithelial cells and the cells which have undergone epithelial-mesenchymal-transition 
(EMT). NRAGE functions differently in the nucleus and cytoplasm affecting transcription 
regulation or adherens junction kinetics.         
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Results 
Ankyrin-G interacts with MAGE family protein NRAGE: NRAGE has previously 
been shown to interact with the netrin receptor Unc5H1, a protein known to contain the 
ZU5-UPA-Death domain supermodule (Wang et al., 2009). This supermodule is 
conserved in other proteins such as PIDD (p53 induced death domain protein) and 
ankyrins (ankyrin-R, ankyrin-B, and ankyrin-G). Based on the Unc5 and NRAGE 
interaction, we tested the interaction between ankyrin-G and NRAGE. Experiments 
performed with mammary epithelial cell (MCF10a and HMLE) lysates suggested that 
ankyrin-G and NRAGE form a complex in cells (Fig.1).  
 
 
 
 
 
 
 
 
 
 
Fig.1. Ankyrin-G interacts with NRAGE in mammary epithelial cells. The cell 
lysates of HMLE and MCF10a cells were subjected to immunoprecipitation either 
using control serum (C) or anti-ankyrinG (A) serum and the Protein A enriched 
lysates were subjected for ankyrin-G and NRAGE immunoblots. (N≥2) 
The specificity of ankyrinG-NRAGE interaction was tested using transient 
knockdown approach. We knocked down NRAGE or ankyrin-G in HMLE and MCF10a 
cells and the cell lysates were used for ankyrin-G immunoprecipitation. The NRAGE 
knockdown abolished the ankyrinG-NRAGE interaction whereas ankyrin-G knockdown 
substantially affected immunoprecipitation efficiency (fig.2). This observation confirmed 
that the interaction between NRAGE and ankyrin-G is specific.  
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Fig.2. Ankyrin-G interacts with NRAGE in HMLE and MCF10a cells. The cell 
lysates of HMLE and MCF10a cells were subjected to immunoprecipitation either 
using control serum (C) or anti-ankyrinG (A) serum and the Protein A enriched 
lysates were subjected for ankyrin-G and NRAGE immunoblots. (N≥2) 
We also tried to co-immunoprecipitate NRAGE and blot for ankyrin-G but few 
existing ankyrin-G antibodies recognized non-specific bands which interfered with the real 
ankyrin-G band on immunoblots. To overcome this limitation, we stably expressed 
retroviral ANK-105 variant (containing HA-tag) in MCF10a cells and the cell lysates were 
used for NRAGE co-immunoprecipitation. The experimental data suggested that NRAGE 
could immunoprecipitate the exogenous ANK-105 (fig.3). 
 
 
 
 
 
 
 
Fig.3. NRAGE co-
immunoprecipitates stably 
expressed exogenous ANK-105 in 
MCF10a cells. Left panel showing the 
immunoblot of the cell lysates 
expressing HA-ANK105. The cell 
lysates from MCF10a/ANK105 cells 
were immunoprecipitated with NRAGE 
or IgG control and blotted for NRAGE 
and anti-HA antibodies.  
 
 
71 
Characterization of domains requirement for NRAGE and ankyrin-G interaction: 
Ankyrin-G and NRAGE interacted in co-immunoprecipitation experiments (MCF10a and 
HMLE cell lysates). We further wanted to know the domain/s required for these 
interactions. Previously reported interaction indicated that the ZU5-UPA-DD supermodule 
of Unc5H1 was required for NRAGE interaction. Two of the transcript variants of ankyrin-
G, ANK-105 and ANK-120, contain these domains which otherwise lack the membrane 
binding domain (consist of 24 ankyrin repeats, present in membrane localized large 
ankyrin-G isoforms). Exogenous ANK-105 expressed in MCF10a cells could be 
immunoprecipitated by NRAGE (fig.3). The other ankyrin isoform is ANK-120, which 
differs with ANK-105 for the presence of a highly acidic insert within the regulatory C-
terminal domain. We compared the splice variants of ankyrin (ANK-105 and ANK-120) for 
NRAGE interaction in co-transfection experiments. The mammalian expression construct 
for GST or GST-NRAGE was co-transfected with HA-ANK105 or HA-ANK120 in 293T 
cells, lysates were subjected to glutathione sepharose pulldown and enriched lysates 
were processed for HA and GST immunoblots. Both of the ankyrin construct products 
were pulled down with NRAGE whereas GST alone failed to do so (fig.4). The pulldown 
data suggested that the ANK-105 variant binding affinity with NRAGE was higher 
compared to ANK-120, indicating the possible role of C-insert in interfering with the 
ankyrinG-NRAGE interaction. Based on this information, we used ANK-105 constructs for 
screening the NRAGE domain required for interaction. 
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 Fig.4.The presence of c-insert interferes 
with ankyrin-G and NRAGE interaction. 
293T cells were co-transfected with 
GST/GST-NR and ankyrin constructs and the 
pulled down samples were immunoblotted 
with HA and GST antibodies. Right panel 
shows the ANK-105 and ANK-120 domains.
 
To find out the NRAGE domain required for ankyrin-G interaction, we designed 
various domain deleted constructs of NRAGE as a fusion product of GST. The various 
NRAGE constructs were co-transfected with HA-ANK105, and lysates were subjected to 
glutathione sepharose pulldown. The enriched lysates were subjected to anti-HA and 
anti-GST blots. The data suggested that the MAGE domain and C-terminal domains of 
NRAGE were required for ankyrin-G interaction (fig.5). Deletion of the MAGE domain and 
C-terminal domain of NRAGE dramatically reduced the ankyrin-G interaction. 
To investigate the requirement of ankyrin-G domain/s for NRAGE interaction, the 
human ankyrin-G construct was used. Considering that ankyrin-G is a large molecular 
weight protein (~210kd) and doesn’t require its membrane binding domain for NRAGE 
interaction (fig. 3, 4, and 5), we designed an ankyrin-G construct that lacked the 
membrane binding domain (MBD) and first tested if ZU5 domains (ZU5-A and ZU5-B) 
were required for NRAGE interaction.   
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 Fig.5. Ankyrin-G interacts with NRAGE through MAGE domain and C-terminal 
domain. Top panel. Various domain deleted constructs of NRAGE were designed 
as a fusion product of GST. Lower left panel. Interaction between ankyrin-G and 
NRAGE represented as the ratio of HA (ankyrin-G) and NRAGE (GST) pulldown. 
The interaction ratio is the average of three individual experiments. Lower right 
panel. A representative blot showing the pulldown (immunoblot: GST and HA) and 
input lysates (immunoblot: HA).  
 
The constructs used for this experiment lacked MBD and either of ZU5-A or ZU5-B 
domains. These constructs were co-transfected in 293T cells either with GST or GST-
NRAGE, and cell lysates were enriched using glutathione sepharose beads. The 
immunoblot data suggested that deletion of either of the ZU5 domains didn’t affect 
NRAGE interaction (fig.6). Surprisingly, deletion of the ZU5-A domain enhanced 
expression and interaction with NRAGE. In subsequent experiments, we used ankyrin 
constructs lacking both the membrane binding domain as well as ZU5-A domain. The 
other set of constructs designed either lacked the UPA domain or had only the UPA 
domain and was tested for NRAGE interaction. 
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 Fig.6. ZU5 domains of ankyrin don’t 
contribute to NRAGE interaction. Various 
ankyrin constructs deleted for either ZU5-A or 
ZU5-B as indicated in the top panel was co-
transfected with GST or GST-NRAGE in 293T 
cells and lysates were subjected to 
glutathione sepharose beads. The enriched 
lysates and input samples were probed for 
GST (GST or GST-NRAGE) or HA (ankyrin 
constructs).  (N≥3).
The co-transfection experiments followed by glutathione sepharose pulldown 
suggested that the loss of the UPA domain dramatically reduced the interaction. The UPA 
domain alone was sufficient for NRAGE interaction (fig.7). The UPA domain is part of the 
supermodule containing ZU5b-UPA-DD in ankyrin-G, unc5H1 and PIDD proteins. 
Interaction with NRAGE is the first reported function of any UPA domain. It is yet to be 
verified if other UPA domains (specially the previously reported unc5H1 interaction with 
NRAGE) interact with NRAGE. Its biological significance is yet to be determined. Based 
on these data, we hypothesize that the UPA domain might sequester NRAGE in ankyrin-
G based cytoskeleton. 
NRAGE affects Ankyrin-G function and epithelial polarity: NRAGE interacts with 
ankyrin-G and might affect ankyrin-G cellular function. We tested the role of NRAGE on 
ankyrin-G membrane localization. MDCK cells were transfected either with ankyrin-G, 
NRAGE or ankyrin-G/NRAGE. Cells were grown to confluency and co-
immunofluorescence (using HA for NRAGE and ankyrin-G) was performed. 
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Fig.7. NRAGE interacts with 
UPA domain of ankyrin-G. 
Various ankyrin-G constructs 
as mentioned were 
cotransfected with GST or 
GST-NRAGE and lysates 
were subjected to glutathione 
sepharose beads. The 
enriched lysates and input 
samples were probed for GST 
(GST or GST-NRAGE) or HA 
(ankyrin constructs). The ratio 
of pulled down signal to input 
signal was used as interaction 
ratio. (N≥3) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig.8. NRAGE affects cellular and biochemical characteristics of ankyrin-G. 
(a.) NRAGE affects ankyrin-G localization. The rat ankyrin-G constructs were 
transfected with vector or NRAGE (MDCK). The fixed cells were stained for ankyrin-
G and HA. (N≥3) (b.) NRAGE affects ankyrin-G solubility in confluent cells. 
Subconfluent (SC) and confluent (C) MCF10a (-/+NRAGE) cell lysates were 
immunoprecipitated either with control (C) or ankyrin-G (A) antibodies and blotted 
for ankyrin-G. (c) The H1299 cells were transfected with vector, NRAGE, ankyrin-G 
or NRAGE/ankyrin-G and lysates were subjected for immunoblots (anti-HA and 
anti-His) and DNA fragmentation ELISA. The DNA fragmentation values were 
normalized with relative protein amount.
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The data suggested that ankyrin-G localized to the membrane whereas NRAGE 
co-transfection dramatically shifted ankyrin-G to cytoplasm (fig. 8a). Ankyrin-G is resistant 
to detergent solubility in association with cytoskeleton in confluent cells. In subconfluent 
cells, ankyrin-G was more soluble to detergent compared to confluent cells, possibly 
because of difference in cell-cell contact. The subconfluent and confluent cell culture 
(MCF10a-/+ NRAGE) lysates were immunoprecipitated and immunoblotted with ankyrin-
G antibody.    
The immunoprecipitation data suggested that ankyrin-G couldn’t be solubilized 
effectively in confluent cells compared to subconfluent cells in control cells. The cells 
expressing NRAGE showed no obvious difference in detergent solubility, in subconfluent 
and confluent cells (fig. 8b). These data suggest that NRAGE expression results in 
increased detergent solubility of ankyrin-G, probably by affecting membrane localization 
which is also supported by the immunofluorescence data (fig. 8a).  This observation 
suggests that NRAGE might affect membrane properties of ankyrin-G and is otherwise 
required for membrane biogenesis and other related membrane functions (Kizhatil and 
Bennett, 2004). We have previously observed that the overexpression of ankyrin-G 
induces apoptosis. We tested the effect of NRAGE on ankyrin-G induced apoptosis. The 
co-transfection experiment performed in H1299 and cos7 cells suggested that NRAGE 
suppresses ankyrin-G induced apoptosis (fig.8c.).  
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Fig. 9. NRAGE affects cell polarity by affecting adherens junction kinetics.  (a). 
The overexpression of NRAGE affects adheren junction. The MDCK cells were 
transfected with HA-NRAGE or HA-crmA and grown till confluency. The cells were 
stained with DECMA-1 (for E-cadherin) or HA (for NRAGE or crmA) antibodies. 
Experiments were performed in duplicates. (N≥2). (b.) The confluent HMLE/MSCV 
or HMLE-NES-NRAGE cells were treated with EGTA and replaced by Ca2+ 
containing medium and kinetics of adheren junction formation was compared by 
ECIS. Experiments were performed in quadruplicates. (N≥2)  
Ankyrin-G is part of the E-cadherin complex, controls membrane biogenesis and 
regulates E-cadherin membrane localization. Based on NRAGE’s role on ankyrin-G 
functions, we hypothesized that NRAGE might affect E-cadherin localization at the 
adherens junction. To test E-cadherin localization, MDCK cells were transfected either 
with vector or NRAGE and grown to confluency. Fixed cells were stained for E-cadherin 
and HA (NRAGE). The E-cadherin staining patterns (either intact or diffuse) were scored. 
NRAGE overexpression resulted in diffuse E-cadherin localization (fig.9a). The 
overexpression assays are an artificial system and we wanted to test E-cadherin 
functions in a more physiological context using ECIS (electric cell impedence sensing) for 
testing adherens junction kinetics. Cells were treated with EGTA (a known chelator for 
Ca2+, which destabilizes E-cadherin mediated adherens junction), and then the cells were 
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replaced subsequently with Ca2+ containing medium, resulting in the formation of 
adherens junction. Adherens junction kinetics (cell impedence as readout) was compared 
between control and NRAGE expressing HMLE cells. The data suggested that NRAGE 
overexpression (~2-3 folds) significantly affected the adherens junction kinetics and 
showed impaired ability to form cell junctions (fig.9b). These data suggest that NRAGE 
affects adherens junction kinetics and hence epithelial cell polarity. 
NRAGE is an anoikis suppressor: NRAGE suppressed ankyrin-G induced 
apoptosis and affected the adherens junction kinetics. As an apoptosis suppressor, we 
hypothesized that NRAGE might play a role in anoikis (apoptosis suppressed by cell-
extracellular matrix interaction), an apoptosis known to suppress metastasis (Frisch and 
Screaton, 2001). To test the hypothesis, we used the transient knockdown experiments in 
mammary epithelial cells (MCF10a) and endothelial cells (iHUVEC). Transient 
knockdown of NRAGE enhanced anoikis (caspase activity assay as an apoptosis 
readout) in both cell types, MCF10a and iHUVEC cells, suggesting NRAGE as a possible 
anoikis suppressor.  
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Fig.10. NRAGE 
suppresses anoikis in 
epithelial and 
endothelial cells. The 
MCF10a (top panel) 
and iHUVEC (bottom 
panel) cells were 
transiently knocked 
down using control 
(luciferase) or NRAGE 
(N) siRNA. Cells were 
suspended for indicated 
times and cell lysates 
were subjected to 
caspase activity assay. 
(N≥3 for MCF10a cells 
We also explored other well characterized epithelial cell lines such as MDCK and 
HMLE. We stably expressed human NRAGE using retroviral infection followed by 
antibiotic selection. The NRAGE expressing cells were confirmed for NRAGE over-
expression (~2-3 fold expression compared to MSCV control). We further compared 
control and NRAGE expressing cells for anoikis. NRAGE expression suppressed anoikis 
in MDCK cells (data not shown). In HMLE cells we grew cells to confluency and an equal 
amount of cells were suspended in rotating tubes to avoid aggregation and lysates 
collected at different suspension time and assayed for caspase activity (fig.11a). The data 
suggested that NRAGE expressing cells were partially resistant to anoikis. To further test 
if the anoikis sensitivity in HMLE cells were a result of NRAGE overexpression, we 
knocked down NRAGE in cells with exogenous NRAGE. The knockdown of NRAGE 
restored anoikis sensitivity in partially resistant HMLE+NRAGE cells (fig.11b). These data 
suggest that over-expression of NRAGE makes cells resistant to anoikis whereas 
transient knockdown reverses the anoikis sensitivity in partially anoikis resistant cells.  
 
 
 
 
 
 
 
 
 
Fig.11. NRAGE level 
inversely correlates with 
anoikis sensitivity in 
mammary epithelial 
(HMLE) cells. (a). NRAGE 
over-expression affects 
anoikis sensitivity in HMLE 
cells (b). Transient 
knockdown of NRAGE 
restores anoikis sensitivity in 
HMLE/NR cells. The cells 
were treated and suspended 
as mentioned and compared 
for caspase acitivity (Vmax). 
The knockdown was 
confirmed using NRAGE 
and actin (loading control) 
immunoblots. (N≥2).       
 
 
80 
 We also tested the effect of transient knockdown or overexpression of NRAGE on 
anoikis using DNA fragmentation as apoptosis readout. As observed with caspase activity 
assay, NRAGE knockdown or overexpression affected DNA fragmentation in a similar 
fashion. The overall data suggest that NRAGE is an anoikis suppressor. Anoikis is a 
safeguard mechanism against tumor metastasis and its suppression can result in 
increased tumor metastasis and carcinoma. Tumor progression affects anoikis sensitivity 
and we tested if there was any correlation between NRAGE expression with cell type and 
cancer stage.  
NRAGE is overexpressed in Breast cancer cell lines and cells undergone EMT: NRAGE 
was characterized as an anoikis suppressor and predicted to be involved with tumor 
progression. We tested the expression level of NRAGE in various tissue lysates 
(comparing normal and tumor samples), breast cancer cells and cells which have 
undergone EMT (epithelial-mesenchymal-transition). We first compared the protein level 
of NRAGE in various normal and tumor tissue samples (blot obtained from G-Biosciences 
Inc). The immunoblot data suggested that NRAGE was over-expressed in tumor samples 
of uterus, breast, ovary and Head/Neck tissues (fig.12a). We also compared a few breast 
cancer cells with the normal mammary epithelial cell line MCF10a for NRAGE expression. 
NRAGE was upregulated in all the breast cancer cells (MCF7, MDA-MB-231, Au565 and 
BT474) tested (fig.12b).  
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Fig.12. NRAGE is overexpressed in certain tumor types. (a). NRAGE is 
overexpressed in certain tumor tissues. Normal (N) and Tumor (T) lysates from 
various tissues (G-Biosciences Inc.) were compared for NRAGE and β-actin. (b). 
NRAGE is overexpressed in breast cancer cell lines. 10μg total protein from 
various cell lysates of normal (MCF10a) and breast cancer cells (MCF7, MDA-MB-
231, Au565 and BT474 were compared for NRAGE. Equal amount of protein was 
also immunoblotted for β-actin as loading control. (c). EMT up-regulates NRAGE 
expression.  The subconfluent and confluent lysates from HMLE cells or derivates 
expressing E-cadherin shRNA (“HMLE/shEcad”) or the Twist oncogene 
(“HMLE/Twist”) were probed for expression of NRAGE, CD44, E-cadherin, or, as a 
loading control, β-actin.    
All tumor types have been shown to undergo epithelial mesenchymal transition 
(EMT). We wanted to test if cells which have undergone EMT might affect NRAGE 
expression. We utilized a well characterized mammary epithelial cell line, HMLE and its 
EMT counterpart HMLE + shECAD (stable knockdown of E-cadherin) and HMLE + Twist 
(stable expression of Twist oncogene). These cells have previously been characterized 
for anoikis resistance (Onder et al., 2008).  The induction of EMT in this system by either 
method induced NRAGE level, which correlated with the induction of CD44 and 
repression of E-cadherin (fig.12c). Preliminary observations comparing the protein level in 
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tumor samples, breast cancer cells and during EMT induction suggests that NRAGE is 
upregulated during EMT and tumor progression. The NRAGE upregulation in EMT cells 
was confirmed through quantitative PCR, suggesting the involvement of transcriptional 
regulation (Frisch SM, unpublished observation). This study was continued with testing 
the expression level of NRAGE in breast cancer and lung cancer patient samples (48 
samples each). NRAGE transcript was found to be upregulated in all stages (dramatic at 
stage I and III) of breast cancer. Among lung cancer patients, NRAGE upregulation was 
found to be stage dependent (Frisch SM, unpublished observation).    
We extended our study by comparing the NRAGE protein level in various 
carcinoma samples which included colon carcinoma, melanoma and prostate cancer 
samples using Automated Quantitative Analysis (AQUA), a quantitative 
immunofluorescence technology using two color fluorescence imaging (Camp et al., 
2002). NRAGE was found to be upregulated in colon carcinoma, metastatic melanoma, 
and prostate cancer samples (unpublished data in collaboration with Elizabeth Killiam and 
David Rimm at Yale University, CT).  
NRAGE upregulation during EMT and variety of cancer cells as well as its function 
as anoikis suppressor suggest that NRAGE is a pro-tumorogenic protein and might 
support the tumor progression primarily by suppressing anoikis.      
NRAGE suppresses anoikis and promotes anchorage independent growth in EMT 
cells: EMT cells acquire resistance to anoikis and therefore promote tumor metastasis. 
The EMT cell models of mammary epithelial HMLE (by stable knockdown of E-cadherin 
or Twist overexpression) cells were resistant to anoikis (Onder et al., 2008). Re-
 
 
83 
expression of mouse E-cadherin in HMLE + shECad cells restores sensitivity to anoikis 
resistance (Frisch SM, unpublished observation).  
 
Fig.13. Transient knockdown of NRAGE promotes anoikis in EMT cells. HMLE + 
shECAD cells (a) and (b) and HMLE + Twist cells (c) were transfected with luciferase 
(Luc) or NRAGE siRNA and suspended cell lysates were processed for (a) caspase 
activity (Vmax) or (b) and (c) DNA fragmentation ELISA. The transient knockdown 
was confirmed by NRAGE (NR) immunoblot using actin or GAPDH as loading control. 
(N≥2)  
 
The EMT cells upregulated NRAGE compared to epithelial cells. We tested if 
NRAGE level correlates with anoikis resistance in EMT cells. To test the effect of NRAGE 
in EMT cells, we transiently knocked down NRAGE in HMLE+shEcad or HMLE+Twist 
cells, and cell lysates were assayed for DNA fragmentation or caspase activity (Vmax).  
The NRAGE knockdown enhanced the anoikis in EMT cells, with increased caspase 
activity (fig.13a) and fragmented DNA (fig.13b and 13c) as apoptosis readout. These 
knockdowns didn’t affect the EMT, as far as morphology and E-cadherin expression 
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pattern were tested (unpublished observation). These data suggest that the knockdown of 
NRAGE can partially restore anoikis sensitivity in EMT cell lines.  
Anoikis suppression correlates with anchorage-independent growth in appropriate 
cellular context, when cell cycle regulations are bypassed. We compared the ability for 
HMLE, HMLE+shECAD and HMLE+Twist for anchorage independent growth. The cell 
types which have undergone EMT demonstrated anchorage independent growth in soft 
agar assay far more efficiently than parental HMLE cells. We transiently knocked down 
NRAGE in HMLE+shECAD and HMLE+Twist cells, followed by anchorage-independent 
growth assays on soft agar. The knockdown of NRAGE partially suppressed the 
anchorage independent growth of EMT cells (fig.14a). We also tested the effect of stable 
NRAGE knockdown in tumor cell line MDA-MB-435 for anchorage independent growth. 
Similar to previous observation in EMT cells, NRAGE knockdown suppressed anchorage 
independent growth in MDA-MB-435 cells (fig.14b). Our data indicate that NRAGE level 
correlates with anoikis suppression and anchorage-independent growth in EMT and 
tumor cells, suggesting its possible over-expression effect in tumor cells. NRAGE might 
promote anoikis suppression and anchorage independence growth in certain cellular 
contexts, perhaps by interaction with pro-tumorigenic genes.     
 
 
85 
 Fig.14. NRAGE promotes anchorage independent growth in EMT and tumor 
cells. (a) The HMLE+shECAD and HMLE+Twist cells were transiently transfected 
with luciferase or NRAGE siRNA and plated along with parental HMLE cells for soft 
agar colony assay. The cells were grown for 7-10 days and colonies from 6 wells were 
compared. The average colonies were normalized with colonies in normal plates. 
(N=2). (b) MDA-MB-435 cells were stably selected for control pRS or NRAGE shRNA 
expressing retroviral vectors and knockdown of NRAGE was confirmed. Either 5,000 
(5K) or 10,000 (10K) cells were plated onto 0.7% low melting agarose containing DME 
medium (in 6 replicates) and colonies were compared after 7-10 days. Average colony 
numbers were normalized with colonies in normal wells. (N=2) 
 
NRAGE interacts with oncogenic transcription factor TBX2: There is various 
interaction partners reported to interact with NRAGE. But the effect on anoikis and 
anchorage independent growth can’t be explained by any of these interactions. To 
identify the interacting partner/s which could possibly explain the NRAGE role in anoikis 
and anchorage independence growth, a yeast two-hybrid interaction was performed. The 
screen identified several candidate genes such as TBX2, KIAA0676, DAZAP2, DOCK6, 
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and a previously reported ubiquitin ligase, Praja2 (Sasaki et al., 2002).  TBX2 has 
previously been reported for promoting anchorage independent growth and pro-
tumorogenic activity. We decided to pursue this interaction in mammalian cells using co-
immunoprecipitation experiments. The NRAGE-TBX2 interaction was confirmed in 
MCF10a and HMLE cells (fig.15). TBX2 antibody immunoprecipitation efficiency was very 
poor, so immunoprecipitation in the other direction couldn’t be performed. These 
interactions have also been confirmed in HMLE+shECAD and HMLE+Twist cells (Frisch 
SM, unpublished).        
 
Fig.15. NRAGE interacts with TBX2 in MCF10a and HMLE cells. MCF10a (left 
panel) and HMLE (right panel) cell lysates were immunoprecipitated either with 
control rabbit IgG or rabbit NRAGE antibody. The immunoprecipitated samples 
were probed with TBX2 or NRAGE antibody. TBX2 antibody immunoprecipitation 
efficiency is very poor, though immunoprecipitate showed same band as NRAGE 
antibody (left panel).        
 
To identify the NRAGE domain required for TBX2 interaction, NRAGE domain 
deletion constructs (GST tagged) were co-transfected with FLAG-TBX2 in 293T cells and 
the lysates were pulled down either using FLAG beads or glutathione sepharose followed 
by FLAG or GST/NRAGE immunoblots. The interaction data suggested that TBX2 
interacts with c-terminal domain of NRAGE (fig.16). The c-terminal domain contains about 
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120 amino acids with unknown function, though quite conserved among species (Chomez 
et al., 2001).  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.16. TBX2 interacts with the C-terminal domain of NRAGE. The indicated 
deletion mutants of GST-NRAGE were cotransfected with FLAG-TBX2; protein 
lysates were immunoprecipitated with FLAG-M2 beads (top lanes) or glutathione 
sepharose (bottom lane) beads and analyzed on a western blot for FLAG and GST.  
The ratios of FLAG:GST signal were quantitated and plotted to indicate the relative 
degree of interaction for each deletion construct, normalized against the expression 
level of each NRAGE deletion mutant (arbitrary units). The NRAGE antibody is raised 
against the peptide representing domain homologous to DNA Pol III, so pulldown 
band related to construct C is not recognized by NRAGE antibody. (N≥3).     
In the yeast 2-hybrid screen, there were many TBX2 clones identified as NRAGE 
interaction partners. The shortest cDNA containing clone found to have part of the 
repression domain (RD) near the c-terminal domain. In pulldown experiments, the 
repression domain of TBX2 was sufficient to pulldown NRAGE whereas expression 
construct lacking repression domain failed, suggesting that TBX2 repression domain as 
 
 
88 
NRAGE interaction domain. NRAGE interaction with the repression domain suggests a 
possible regulation in TBX2 dependent gene repression function. 
TBX2 functionally co-operates with NRAGE: TBX2 is reported to have anti-
apoptotic as well as pro-tumorigenic activities such as counteracting cisplatin (DNA 
damaging agent) induced apoptosis (Davis et al., 2008). The TBX2 also promoted 
anchorage-independent growth in SW13 adenocarcinoma cells and mouse embryo 
fibroblast lacking retinoblastoma and its pocket proteins (Ismail and Bateman, 2009; 
Vormer et al., 2008).  
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Fig.17. TBX2 and NRAGE interactions are functionally significant. TBX2 is an 
anoikis suppressor. (a) MCF10a cells or (b) HMLE cells were transfected with siRNA 
duplexes  specific for luciferase (“siLuc”), NRAGE (“siNR”) or TBX2 (“siTBX2”) and 
assayed for anoikis by DNA fragmentation (y-axis represents optical density units). 
Both cell lines were assayed for anoikis at about 42 hours post-transfection; 
suspension time:  6 hours (MCF10a); 8 hours (HMLE). The knockdown was confirmed 
by immunoblot analysis. (c) TBX2 knockdown restores anoikis sensitivity in 
MCF10a+NRAGE cells. MCF10a+NRAGE cells were transfected with siRNA for 
luciferase (“siLuc”) or TBX2 (“siTBX2”) and assayed for anoikis by DNA fragmentation 
along with MCF10a+pMIG cells. The knockdown was confirmed by immunoblots.        
With NRAGE interaction, we were curious to see whether TBX2 regulates anoikis 
as well. The transient knockdown of TBX2 enhanced anoikis in MCF10a (fig.17a) and 
HMLE cells (fig.17b), suggesting its role similar to NRAGE as anoikis suppressor.We 
tested the effect of TBX2 on MCF10a + NRAGE; a partially anoikis resistant cells.The 
transient knockdown of TBX2 restored anoikis sensitivity in NRAGE-expressing cells 
(fig.17c). The data suggested that NRAGE effect on anoikis resistance required TBX2, 
confirming their co-operation for suppressing anoikis.  
SW13 adrenocortical carcinoma cells have previously been shown to become 
anchorage-independent in presence of TBX2 over-expression (Ismail and Bateman, 
2009). We tested whether NRAGE was required for promoting TBX2-dependent 
anchorage independent growth. SW13 cells were stably selected for TBX2 expression, 
followed by stable downregulation of NRAGE using retroviral shRNA. The anchorage 
independent growth was compared with control cells expressing pRS vector control.  The 
knockdown of NRAGE suppressed anchorage-independent growth without affecting 
normal growth under attached conditions (fig.18). These data confirm the co-operation 
between NRAGE and TBX2 in promoting anchorage independent growth.  
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Fig.18. NRAGE is required for 
TBX2-dependent anchorage-
independent growth.  SW13 
adrenocortical carcinoma cells 
that stably over-expressed 
TBX2 were infected with 
NRAGE shRNA retrovirus or 
the empty retrovirus vector 
pRS, producing stable 
knockdown cells as shown in 
the western blot. Cells were 
assayed for growth in soft agar. 
The p-value for the difference 
was p=0.001.   
TBX2 has also been shown to promote anoikis resistance in EMT cells 
(HMLE+shECAD and HMLE+Twist cells) (Frisch SM, unpublished). The overall data 
suggest that the NRAGE and TBX2 co-operate for anoikis resistance and anchorage 
independent growth and so, hypothesized to promote tumor progression and metastatic 
growth. 
Ankyrin-G regulates NRAGE nucleocytoplasmic localization: NRAGE interacts with 
proteins such as transcription factors, membrane receptors or proteins with cytoplasmic 
function and so can localize to nucleus, membrane or cytoplasm. In neuronal PC12 cells, 
NRAGE localized to membrane in response to NGF treatment (Salehi et al., 2000). In 
another context, co-expression of NRAGE and homeodomain protein Msx2 promoted 
NRAGE nuclear localization (Matsuda et al., 2003). The localization patterns of NRAGE 
in epithelial and EMT cells are not well characterized. We hypothesized that interacting 
partners such as ankyrin-G might regulate the nucleocytoplasmic transport of NRAGE.   
To test the hypothesis that ankyrin-G might regulate NRAGE nucleocytoplasmic 
transport, we used the fibrosarcoma cell line HT1080, expresses very low level of 
endogenous ankyrin-G (unpublished observation). The cells were transfected either with 
HA-NRAGE and vector control, ankyrin-G or dominant negative ankyrin-G lacking UPA 
domain (ΔUPA). NRAGE on its own localized to nucleus whereas co-expression of 
ankyrin-G sequestered NRAGE in cytoplasm. Expression of ankyrin-G lacking UPA failed 
to sequester NRAGE in nucleus (fig.19a). The data suggested that ankyrin-G sequesters 
NRAGE in cytoplasm which otherwise localizes to nucleus. Transient overexpression of 
NRAGE and ankyrin-G is an artificial system, so we tested the effect on ankyrin-G on 
NRAGE localization in more physiological context.  
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Fig.19. Ankyrin-G controls NRAGE localization. (a) Over-expressed ankyrin-G 
sequesters NRAGE in the cytoplasm. HT1080 cells were cotransfected with 
expression constructs encoding FLAG-tagged human ankyrin-G (210 kDa isoform), an 
NRAGE-non-binding ankyrin-G deletion mutant, ΔUPA, or empty vector together with 
HA-NRAGE.   Cells were then fixed and stained for FLAG-ankyrin-G, HA-NRAGE or 
chromatin (DAPI).  The histogram represents the fraction of HA-NRAGE that was 
nuclear; N=30, p=0.001. (b) Depletion of ankyrin-G facilitates the accumulation of 
NRAGE in the nucleus.  MCF10a cells were transfected with siRNA for ankyrin-G (“si-
Ank”) or luciferase (“si-Luc”).  Cells were then treated with leptomycin B for 30 minutes 
prior to fixation and stained for NRAGE (green, left panel) or chromatin (DAPI, blue) or 
B-catenin (red, right panel)). For the merged images, color intensities were adjusted to 
provide optimal color balance. (N≥2)  
We used the MCF10a cells and knocked down ankyrin-G through transient 
transfection. Before fixing cells, leptomycin B (inhibitor of Crm1 dependent nuclear export) 
was treated for 30 minutes. Transient knockdown of ankyrin-G accumulated NRAGE 
protein in nucleus compared to luciferase siRNA-treated control cells (fig.19b). As a 
control, beta catenin staining for luciferase and ankyrin-G knocked down cells was 
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performed and no noticeable difference was observed. To rule out the NRAGE antibody 
artifact, we performed similar experiment in MCF10a+NRAGE cells and HA staining was 
performed. As observed previously, transient knockdown of ankyrin-G accumulated 
exogenous NRAGE in nucleus (fig.20). These results indicated that ankyrin-G regulated 
the nucleocytoplasmic localization of NRAGE by direct interaction. 
 
 
 
 
 
 
 
 
Fig.20. Ankyrin-G affects the 
localization of exogenous NRAGE in 
MCF10a cells. Depletion of ankyrin-G 
facilitates the accumulation of HA-NRAGE 
in the nucleus.  MCF10a + NRAGE cells 
were transfected with siRNA for ankyrin-G 
(“si-Ank”) or luciferase (“si-Luc”).  Cells 
were then treated with leptomycin B for 30 
minutes prior to fixation and stained for 
HA (red) or chromatin (DAPI, blue). For 
the merged images, color intensities were 
adjusted to provide optimal color balance. 
(N≥2)  
EMT promotes nuclear localization of NRAGE: Induction of EMT either by stable 
knockdown of E-cadherin or Twist overexpression in HMLE suppressed ankyrin-G 
expression when compared with parental HMLE cells (~210 kDa, fig. 1C, chapter 3). We 
tested if these cells have different NRAGE localization pattern in comparison to parental 
HMLE cells and whether they correlate with the observations made in MCF10a-/+ankyrin-
G cells (fig.19 and 20). The NRAGE localization data suggested that the cells undergone 
EMT (HMLE+shECAD and HMLE+Twist) accumulate NRAGE in the nucleus significantly 
compared to the control HMLE cells (fig.21a). We also made an interesting observation 
that NRAGE protein fused to multiple SV40 T-antigen nuclear localization signals (NLS) 
were selected stably in HMLE cells, displayed a cytoplasmic localization pattern 
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compared to predominantly nuclear localization in HMLE+Twist cells. These observations 
suggest that the epithelial cells show strong selection for cytoplasmic NRAGE; probably 
ankyrin-G sequesters NRAGE in cytoplasm (fig.21b).  These observations indicate that 
the ankyrin-G downregulation in the cells which have undergone EMT as well as in the 
variety of human tumors, promote the nuclear localization of NRAGE.  
  
 
 
 
 
 
 
 
 
 
 
     
 
 
 
Fig.21. EMT promotes nuclear accumulation of NRAGE.  (a) The HMLE, 
HMLE+shEcad or HMLE+Twist cells were treated with leptomycin B for thirty minutes 
prior to fixation and staining for NRAGE (green) or chromatin (DAPI, blue); p=0.001. 
(N≥3) (b)  NRAGE-NLS accumulates in the nucleus of cells over-expressing Twist.  
Normal HMLE cells or HMLE+Twist cells were stably transduced with an HA-NRAGE-
NLS-expressing retrovirus.  Cells were fixed and stained for NRAGE (green) and 
chromatin (DAPI, blue) without leptomycin B treatment. For the merged images, color 
intensities were adjusted to provide optimal color balance. (N≥2)   
 
To test if NLS-NRAGE localization in HMLE cells were mainly due to the presence 
of ankyrin-G, we transiently knocked down ankyrin-G from HMLE + NLS-NRAGE cells. 
The loss of ankyrin-G showed significantly higher nuclear NRAGE compared to luciferase 
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siRNA transfected control cells (fig.22). Considering that the NLS-NRAGE is over-
expressed and all the cells were not positive for siRNA transfection, relocalization data 
confirmed our hypothesis and previous observations that ankyrin-G regulated NRAGE 
nucleocytoplasmic transport. 
 
 
 
 
 
 
 
 
 
Fig.22. The knockdown 
of ankyrin-G partially 
relocates exogenous 
NLS-NRAGE to nucleus. 
HMLE + NLS-NRAGE 
expressing cells were 
transfected with luciferase 
(Luc) or ankyrin-G (ANK3) 
siRNA and cells were 
stained for HA (green) 
and DAPI (blue) without 
treating with leptomycinB. 
~30 cells in each group 
were subjected for 
quantitation. (P-value < 
0.001)    
 
Ankyrin counteracts NRAGE-mediated transcription repressor function: NRAGE 
interacts with transcription factors such as DLX5, Msx2, and Tbx2 etc. Our data indicated 
that NRAGE sub-cellular localization depends on the level of ankyrin-G. NRAGE has 
previously been reported to regulate Dlx5-dependent transcription activity using luciferase 
assay based mammalian 2-hybrid assay (Masuda et al., 2001; Sasaki et al., 2002). We 
used similar strategy and used the c-terminal deletion construct of Dlx5 fused to Gal4 
DNA binding domain (pBind-Dlx5ΔC) and transfected with Gal4 activation domain 
containing construct (pG5-luc) fused with luciferase gene. Co-transfection of pBind-
Dlx5ΔC and pG5-luc activated transcription compared to pBind vector control. We then 
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tested the effect of NRAGE knockdown in Dlx5 dependent transcription activity. NRAGE 
knockdown enhanced Dlx5 mediated transcriptional activity, suggesting its role as 
transcription repressor (fig.23). We further tested the role of ankyrin Dlx5 transcriptional 
activity. The over-expression of ankyrin-G enhanced Dlx5 dependent luciferase activity, 
whereas transient knockdown of ankyrin-G repressed Dlx5 mediated transcription activity 
(Fig.24). The effect of ankyrin-G expression on Dlx5 transcription activity matched with 
our hypothesis based on NRAGE-mediated transcriptional repression and ankyrin effect 
on NRAGE localization. This is the first ever observation that a cytoskeletal protein 
ankyrin-G regulates transcription, possibly by counteracting NRAGE dependent 
transcriptional repression. The physiological relevance of ankyrin-G/NRAGE regulation of 
Dlx5 mediated transcription activity is presently unknown.  
       
 
 
 
 
 
 
 
 
 
 
 
Fig.23. NRAGE represses Dlx-5 dependent transcription activity. The pBIND-
Dlx5ΔC and pG5-luc reporter plasmids were transfected either with control (pRS) or 
NRAGE shRNA constructs (NR-1 and NR-2) in 293T cells. The cell lysates were 
used for firefly luciferase activity assay and values were normalized with renilla 
luciferase assay. The knockdown was confirmed by NRAGE immunoblots and actin 
was used as loading control. (N≥2)     
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 Fig.24.Ankyrin-G promotes Dlx-5 mediated transcription activity. The pBIND-
Dlx5ΔC and pG5-luc reporter plasmids were transfected either with control or ankyrin-
G vectors (top panel) and either with control (pRS) or ankyrin shRNA (bottom panel). 
The cell lysates were used for firefly luciferase activity assay and values were 
normalized with renilla luciferase assay. The knockdown was confirmed by 
immunoblots. (N≥2)     
 
The novel NRAGE-interacting partner TBX2 is a well known transcriptional 
repressor and its best characterized target is tumor suppressor p14-ARF (Jacobs et al., 
2000; Prince et al., 2004; Rodriguez et al., 2008). Experiments performed in our 
laboratory using luciferase based transcriptional assay and chromatin 
immunoprecipitation (CHIP) suggested that NRAGE acted as a co-repressor for TBX2 
mediated p14-ARF repression through binding to T-Box element. NRAGE and TBX2 
suppress anoikis and repress p14-ARF expression. Do NRAGE and TBX2 anoikis 
suppression depend on ARF? Is ARF an anoikis promoter? We decided to test p14-
ARF/p19-ARF for its role in anoikis.     
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ARF regulates anoikis: NRAGE and TBX2 co-operate in suppressing anoikis and 
promoting anchorage independent growth. TBX2 target p14-ARF has been shown to 
have pro-apoptotic activities. We hypothesized that p14-ARF promoted anoikis. To test 
the effect of p14-ARF (p19-ARF in mouse) on anoikis, we compared p19ARF-knockout 
mouse embryo fibroblasts (MEFs) or matched wild-type control MEFs, immortalized with 
SV40 T-antigen cells for anoikis. The p19ARF-knockout MEFs were dramatically less 
sensitive to anoikis compared to the wild-type MEFs (fig.25), confirming that p14-
ARF/p19-ARF promoted anoikis, indicating a novel function for this tumor suppressor 
gene. 
  
 
 
 
 
 
 
Fig.25. The tumor 
suppressor p19-ARF 
promotes anoikis. 
P19-null or wt MEFs 
were suspended and 
cell lysates were 
collected at 0, 6 and 24 
hours. The lysates were 
subjected for DNA 
fragmentation ELISA. 
The 0 hour values were 
subtracted. 
We also compared two MCF10a cell variants, one obtained from ATCC which lack 
both alleles of ARF and the other obtained from Karmanos Cancer Center (K) which 
contains one functional allele of ARF locus (Frisch SM, unpublished). We transiently 
knocked down NRAGE in both the MCF10a variants (ATCC and K) and compared the 
cell lysates for anoikis. The MCF10a cells lacking both ARF alleles (ATCC) found to be 
completely resistant to anoikis and NRAGE didn’t affect anoikis sensitivity either (fig.26). 
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Fig.26. NRAGE effect on 
anoikis requires ARF. MCF10a 
cell variant from Karmanos 
Center (K) or ATCC (lack ARF 
locus) were compared for anoikis 
after NRAGE or luciferase 
knockdown. The lysates were 
made at 6 hrs after suspension 
and analyzed for DNA 
fragmentation.
 
Expression of nuclear NRAGE suppresses anoikis: NRAGE localization is 
controlled by ankyrin-G in epithelial cells. The stable over-expression of NRAGE shows 
cytoplasmic localization. We wanted to know if nuclear NRAGE could suppress anoikis. 
The stably expressed NRAGE with multiple SV40 T-antigen nuclear localization signals 
(NLS) showed predominantly cytoplasmic localization in epithelial cells (MCF10a and 
HMLE). Individual clones showing cytoplasmic or nuclear localization were selected and 
compared for anoikis sensitivity. The first set of cells compared for anoikis were HMLE + 
NLS-NRAGE1 (with cytoplasmic localization) and HMLE + NLS-hNR3 (nuclear 
localization) (fig.27a). Surprisingly, both of these HMLE clones suppressed anoikis 
significantly (fig.27b). Another HMLE clone, NLS-hNR25 expressing nuclear localization 
was compared for anoikis with control cells (pMIG) and it suppressed anoikis equally well 
as NRAGE with coding sequence (CDS-hNR) (fig.27c.). Similarly, MCF10a cells with 
nuclear NRAGE (NLS1 and NLS8) were compared for anoikis, behaved similar to HMLE 
cells and suppressed anoikis compared to control cells (fig.27d.). This data suggested 
that NRAGE localized in nucleus suppressed anoikis. The cytoplasmic expressing 
NRAGE (HMLE + NLS-NR1) also suppressed anoikis. To test the effect of cytoplasmic 
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NRAGE, NES-NRAGE (containing nuclear exclusion signal) expressing HMLE and 
MCF10a cells were generated and compared for anoikis. 
 
            
 
Fig.27. Expression of nuclear NRAGE suppresses anoikis. (a) Immunofluorescence 
images of two clones of HMLE stained for HA/DAPI (green/blue). (b) The HMLE clones 
with cytoplasmic or nuclear NRAGE expression were compared for anoikis using 
caspase activity assay. (c) HMLE+NLS-hNR cells with nuclear NRAGE were compared 
with control (pMIG) and CDS-hNR (coding sequence) for anoikis (6 hrs suspension; 
DNA fragmentation). (d) MCF10a cells expressing nuclear NRAGE (NLS-NR1 and 
NLS-NR8) were compared for anoikis (6 hrs suspension; DNA Fragmentation). 
Cytoplasmic NRAGE suppresses anoikis: The HMLE and MCF10a cells were 
selected for NRAGE containing nuclear exclusion signal (NES-NRAGE). Selection of 
cytoplasmic expressing NRAGE (NES-NRAGE) clones was far easier compared to 
nuclear expressing NRAGE as majority of cells showed transgene expression. The 
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anoikis data suggested that cytoplasmic NRAGE (NES) suppressed anoikis equally well 
as CDS-NRAGE (with coding sequence) or NLS-NRAGE in subconfluent and confluent 
MCF10a and HMLE cells (fig.28). We have observed previously that loss of ankyrin-G 
during EMT promoted nuclear localization of NRAGE (fig.21-24). In presence of ankyrin-
G, NRAGE localized to cytoplasm and its overexpression affected cell polarity and 
adherens junction kinetics (fig.8 and fig.9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 28. Cytoplasmic NRAGE suppresses anoikis in HMLE and MCF10a cells. (a) 
HMLE cells expressing MSCV, CDS-NRAGE, NES-NRAGE and NLS-NRAGE or (b) 
MCF10a cells expressing MSCV, CDS-NRAGE and NES-NRAGE were compared for 
subconfluent (left panel) or confluent anoikis (right panel). (N≥2) 
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NRAGE promotes survival signaling in cells lacking cell-extracellular matrix 
interaction: The expression of cytoplasmic NRAGE (NES-NRAGE) suppressed anoikis in 
HMLE and MCF10a cells. We hypothesized that NRAGE might regulate signaling 
process, an effect of misregulated adherens junction function. We first tested the effect of 
NRAGE knockdown on AKT and p38 activation in early detached MCF10a cells. The 
immunoblot data suggested that NRAGE retained AKT phosphorylation in early detached 
cells (fig.29). It is previously reported that retention of activated AKT suppress anoikis and 
promote survival in suspended cells (Frisch and Ruoslahti, 1997). We made similar 
observations in exogenous NRAGE expressing confluent MCF10a cells in early detached 
cells. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Fig.29. NRAGE promotes survival through activated AKT. MCF10a cells were 
transfected either with NRAGE (N) or luciferase (L) siRNA. The confluent cells were 
suspended for above mentioned time and lysates were used for estimation of p-p38 
(T180/Y182), total p38, pAKT (S473), total AKT, β-tubulin and NRAGE. The ratio of 
pAKT/AKT and p-p38/p38 was measured using image J software. 
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Based on NRAGE effect on AKT activation during short term suspension, we 
decided to test the signaling events using low density culture in long term suspension. 
The MCF10a (-/+ NRAGE) cells were suspended and lysates were collected at various 
time points. The immunoblots were compared for various signaling molecules such as 
phospho-AKT, phospho-FAK, phospho-ERK and phospho-EGFR. The data suggested 
that the NRAGE over-expression affected the AKT and FAK activity whereas effect on 
EGFR and ERK was very minimal in long time suspension (fig. 30a).       
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Fig.30. NRAGE overexpression activate signaling events during cell-extracellular 
matrix dissociation. (a) NRAGE overexpression activates FAK/AKT signaling in 
suspended cells. Subconfluent MCF10a/pMIG or MCF10a/NRAGE cells were 
suspended and cell lysates were made at 0, 6, 12 and 24 hours. Lysates were compared 
for pEGFR (pY1086), EGFR, pFAK (pY397), FAK, pERK (pT202/pY204), ERK, pAKT 
(pS473), AKT and Bim. (b) NRAGE overexpression interferes with FAK/AKT signaling in 
adhesion assay. MCF10a/pMIG and MCF10a/NRAGE cells were trypsinized and plated 
on collagen coated wells and lysates were collected after cell attachment. The cell 
lysates were compared for pEGFR (pY1086), pFAK (pY397), FAK, pAKT (pS473) and 
AKT.
We further compared the effect of NRAGE overexpression in collagen re-adhesion 
assay where MCF10a (-/+NRAGE) cells were plated on collagen and collected lysates 
were immunoblotted for pFAK/FAK, pAKT/AKT, and EGFR. Surprisingly, NRAGE 
expressing cells were dramatically deficient in AKT and FAK activation in cells attached 
on collagen (fig.30b). The data indicate that NRAGE promotes survival signaling through 
FAK and AKT in suspended cells and interferes with early signaling events in cells re-
attached on collagen. The overall data suggest that NRAGE overexpression affected pro-
survival signaling events during suspension and inhibited signaling events during early 
adhesion. It is yet to be verified if the signaling events during suspension correlate with 
the cell adhesion, polarity and adherens junction kinetics. The cells dissociated from 
extracellular matrix with better pro-survival signaling could promote cell metastasis.  
Discussion 
The MAGE family protein, NRAGE/MAGE-D1 was identified as Unc5H1 interaction 
partner in a yeast 2-hybrid screen using E18 murine brain tissue cDNA library. The 
MAGE homology domain and C-terminal domain of NRAGE interacted with ZU5 domain 
and adjacent sequence (Williams et al., 2003). These unc5H1 regions were later 
characterized as ZU5-UPA-DD supermodule, homologous in Unc5, PIDD and ankyrins 
(Wang et al., 2009). Based on structural homology, NRAGE was tested for interaction 
with ankyrin-G. The interaction was confirmed in HMLE and MCF10a cells. The UPA 
(homolgous in Unc5, PIDD and ankyrin) domain of ankyrin-G was identified as domain 
responsible for interaction with MAGE homology domain and C-terminal domain of 
NRAGE (fig.1, 2, 3, and 5). The ZU5-A domain (part of spectrin binding domain) and C-
insert (in C-terminal regulatory domain) of ankyrin-G interfered with NRAGE interaction 
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(fig. 4, 6, and 7).  The ZU5-A interference to NRAGE interaction might be due to closed 
structural conformation. Our data suggest that ZU5-A domain alone could interact with 
NRAGE (unpublished observation). In invitro interaction studies, NRAGE competed with 
spectrin for ankyrin-G binding (Frisch SM, unpublished observation). Overexpression of 
NRAGE affected localization and detergent solubility of ankyrin-G (fig.8). NRAGE also 
suppressed ankyrin-G induced apoptosis, affected E-cadherin localization and adherens 
junction kinetics (fig. 8 and 9). NRAGE has previously been implicated in disrupting E-
cadherin/beta catenin complex and so might affect the adherens junction and cell polarity 
(Xue et al., 2005).  
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Fig.30. NRAGE suppresses anoikis and anchorage independent growth by 
regulating various cellular processes. Ankyrin-G interacts with NRAGE and 
regulates its nucleocytoplasmic transport. NRAGE overexpression promotes 
anchorage independence and anoikis resistance in cells. NRAGE functionally co-
operates with TBX2 in promoting anchorage independence and anoikis suppression. 
The mechanisms required for anoikis resistance may depend on NRAGE cellular 
localization.   
Loss of cell-extracellular matrix interaction promotes cytoplasmic localization (from 
cytoskeleton) of ankyrin-G with elevated protein level (chapter 3; fig.2 and fig.3). To mimic 
this condition invitro, we overexpressed ankyrin-G. NRAGE suppressed ankyrin-G 
dependent apoptosis. Based on this observation, we went ahead and tested the effect of 
NRAGE on anoikis. By transient knockdown and stable overexpression, we established 
NRAGE as an anoikis suppressor. The NRAGE role as anoikis suppressor correlated well 
with its expression in breast cancer cells and EMT. Our data also support previous 
observations of NRAGE upregulation in lung, kidney and head/neck carcinoma 
(Bhattacharjee et al., 2001; Boer et al., 2001; Ginos et al., 2004).  
We performed yeast 2-hybrid screening and identified oncogenic transcription 
repressor TBX2, as NRAGE interacting partner. TBX2 and NRAGE co-operated for 
suppressing anoikis sensitivity and promoting anchorage independent growth. NRAGE is 
predicted to be TBX2 co-repressor and its role is yet to be verified in physiological 
context. TBX2 is known to repress p14-ARF/NDRG1 and NRAGE function as a co-
repressor is yet to be verified (Jacobs et al., 2000; Prince et al., 2004; Redmond et al.). 
NRAGE was identified as lateral membrane protein ankyrin-G interaction partner. 
We hypothesized that ankyrin-G might regulate NRAGE nucleocytoplasmic transport.  
Ankyrin-G expression sequestered NRAGE in cytoplasm whereas dominant negative 
expression construct lacking UPA domain (ankyrin-GΔUPA) failed to do so, indicating that 
the direct interaction was responsible for NRAGE cellular localization. Based on ankyrin-
G effect on NRAGE localization, we tested the effect of ankyrin on Dlx5 transcription 
activity. Ankyrin-G counteracted NRAGE mediated regulation on Dlx5 transcriptional 
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activity (fig.23 and 24). Here we show a novel function of cytoskeletal protein ankyrin-G in 
regulating nucleocytoplasmic transport and transcriptional activity.  
We further tested if cytoplasmic or nuclear forms of NRAGE suppress anoikis. 
Surprisingly, both forms suppressed anoikis. The nuclear form of NRAGE affects anoikis 
by co-operating with TBX2. The mechanism of cytoplasmic NRAGE in anoikis is not clear. 
NRAGE affected ankyrin-G sub-cellular localization and adherens junction kinetics, hence 
we hypothesized that NRAGE might promote pro-survival signaling process. In the 
experimental set up, NRAGE promoted pro-survival signaling in cells dissociated from 
extra-cellular matrix and inhibited early signaling events in collagen adhesion assay 
(fig.30).  
Our data suggested that ankyrin-G interacting MAGE family protein NRAGE 
suppressed anoikis. Ankyrin-G sequesters NRAGE in cytoplasm. During EMT, ankyrin-G 
is downregulated, which in turn allows NRAGE to localize to nucleus. NRAGE co-
operates with TBX2 in suppressing anoikis and promoting anchorage independent 
growth. Cytoplasmic NRAGE also suppressed anoikis, probably by affecting ankyrin-G 
mediated membrane function, adherens junction kinetics, and promoting pro-survival 
signaling in cells dissociated from extracellular matrix (fig.30). 
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